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 Abstract 
Bacteria can exist as planktonic, the lifestyle in which single cells exist in suspension, and 
as biofilms, which are surface-attached bacterial communities embedded in a self-
produced matrix. Most of the antibiotics and the methods for antimicrobial work have 
been developed for planktonic bacteria. However, the majority of the bacteria in natural 
habitats live as biofilms. Biofilms develop dauntingly fast high resistance towards 
conventional antibacterial treatments and thus, there is a great need to meet the 
demands of effective anti-biofilm therapy. 
In this thesis project it was attempted to fill the void of anti-biofilm screening methods by 
developing a platform of assays that evaluate the effect that screened compounds have on 
the total biomass, viability and the extracellular polysaccharide (EPS) layer of the 
biofilms. Additionally, a new method for studying biofilms and their interactions with 
compounds in a continuous flow system was developed using capillary 
electrochromatography (CEC). The screening platform was utilized with a screening 
campaign using a small library of cinchona alkaloids. 
The assays were optimized to be statistically robust enough for screening. The first assay, 
based on crystal violet staining, measures total biofilm biomass, and it was automated 
using a liquid handling workstation to decrease the manual workload and signal 
variation. The second assay, based on resazurin staining, measures viability of the biofilm, 
and it was thoroughly optimized for the strain used, but was then a very simple and fast 
method to be used for primary screening. The fluorescent resazurin probe is not toxic to 
the biofilms. In fact, it was also shown in this project that staining the biofilms with 
resazurin prior to staining with crystal violet had no effect on the latter and they can be 
used in sequence on the same screening plate. This sequential addition step was indeed a 
major improvement on the use of reagents and consumables and also shortened the work 
time. As a third assay in the platform a wheat germ agglutinin based assay was added to 
evaluate the effect a compound has on the EPS layer. Using this assay it was found that 
even if compounds might have clear effect on both biomass and viability, the EPS layer 
can be left untouched or even be increased. This is a clear implication of the importance 
of using several assays to be able to find “true hits” in a screening setting.  
In the pilot study of screening for antimicrobial and anti-biofilm effects using a cinchona 
alkaloid library, one compound was found to have antimicrobial effect against planktonic 
bacteria and prevent biofilm formation at low micromolar concentration. To eradicate 
biofilms, a higher concentration was needed. It was also shown that the chemical space 
occupied by the active compound was slightly different than the rest of the cinchona 
alkaloids as well as the rest of the compounds used for validatory screening during the 
optimization processes of the separate assays.  
Review of the literature 
14 
 
1 Review of the literature 
1.1 Biofilms 
Biofilms are defined in many ways, “a structured community of bacterial cells enclosed in 
a self-produced polymeric matrix and adherent to an inert or living surface”, given by 
Costerton et al. (1999) is maybe the most explanatory definition. Every description of 
biofilms concludes similarly that a biofilm consists of the bacteria (single or 
multispecies), the matrix and the surface to which the whole structure is attached (Dunne 
2002). Practically any surface, living or non-living can be targeted for bacteria 
colonization and, thus, biofilm formation. Surfaces can range from rocks in a water 
stream (Costerton et al. 1978, Henrici 1933), paper industry machinery (Kolari et al. 
2001) to plants, human and animal lungs, noses, ears, and wounds etc. Biofilms have been 
known as such since the 1970s and 1980s when Costerton and his coworkers defined 
how bacteria stick to a surface and further studied the biofilm phenomenon (Costerton et 
al. 1978, Costerton et al. 1987). Prior to that, Henrici in the 1930s, came to the conclusion 
that bacteria in fresh water are not growing planktonically but in clusters attached to 
solid, even glass, surfaces (Henrici 1933). However, even earlier, Antonie van 
Leeuwenhoek, who was the first person to be able to study bacteria under a microscope, 
or animalculi as he referred to them in the 17th century, was actually studying biofilms 
because he scraped the microbes off his teeth. Biofilms in dental plaques are actually one 
of the most studied areas of biofilm research (Burmølle et al. 2010). Additionally, biofilm 
contamination of prosthetic devices is another area with an intense research focus 
(Schinabeck and Ghannoum 2006).  
1.1.1 Formation of biofilms 
Why are biofilms formed in the first place? At some point in the evolution of prokaryotes, 
biofilm formation was likely to be advantageous for survival. There are many theories as 
to why biofilms are the preferred lifestyle by so many bacteria. First, the surface provides 
stability in the growth environment by localizing the cells in close proximity. Secondly, 
the biofilm formation offers protection from a wide range of environmental challenges 
(Hall-Stoodley et al. 2004). It has also been widely discussed how nutrient availability 
affects initiation of biofilm formation. It has been seen that gram-negative bacteria favor 
biofilm formation in nutrient-rich media and in nutrient-deprived surroundings tend to 
return to the planktonic phase of living, based on the theory that the free floating mode 
helps in the search for fresh nutrients (O'Toole et al. 2000). However, the opposite has 
been seen for the gram-negative Escherichia coli where scarce conditions that tend to 
slow down bacterial growth actually favor biofilm formation (Adams and McLean 1999). 
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Figure 1. Formation of a model biofilm on a surface. The formation is divided into steps that 
include initial adhesion, attachment, proliferation, maturation and detachment. Modified from Otto 
(2004) and Pascual (2002). 
1.1.1.1 Adherence and early maturation 
Biofilm formation can be divided into several steps, presented above in figure 1. First, 
there has to be the opportunity for the bacteria to adhere to the surface. In a water 
stream or in a blood vessel with a continuous flow, this is usually not a limiting stage, but 
in surfaces less influenced by flow (i.e., medical implants) the bacteria have to be 
transported into close proximity of the substrate surface so that the attachment can take 
place. A distance of approximately 50 nm can be regarded as close enough for the 
bacteria to initially adhere (Gorman and Jones 2006). The attachment has been found to 
be mediated by electrostatic interactions and van der Waals forces (Pascual 2002). 
Many structural features on the cell surface of bacteria affect the substrate’s surface 
charge and hydrophobicity and, thus, contribute to the attachment step: fimbriae, the 
teichoic acids in the cell wall of gram-positive bacteria, and the liposaccharides in the 
outer cell membrane of gram-negative bacteria (Gorman and Jones 2006). Additionally, 
the environmental conditions and the characteristics of the surface may also affect the 
rate and the extent of attachment of the bacteria. In general, rougher and more 
hydrophobic materials will lead to more and faster development of biofilms (Donlan 
2001). In contrast, less rough materials can also allow fast biofilm formation, due to a 
conditioning film that is formed of proteinaceous molecules on surfaces when they are 
placed into a liquid environment (can consist of anything between bloodstream and a 
freshwater lake) (Donlan 2001, Schinabeck and Ghannoum 2006). Staphylococcus spp. 
adherence is promoted by protein and glycoprotein components on the surface, the most 
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important being fibronectin, fibrinogen and fibrin, but also collagen, elastin, laminin, 
vitronectin and von Willebrand factors have been shown to be involved (Pascual 2002, 
Beenken et al. 2010). Staphylococcus spp. have several specific adhesion promoting 
proteins that comprehensively are called “microbial surface components recognizing 
adhesive matrix molecules” (MSCRAMMs) (Patti et al. 1994). The most important 
proteins, fibronectin, fibrinogen and fibrin, have also been shown to induce adhesion for 
gram-negative bacteria as well as Candida albicans fungi (Schinabeck and Ghannoum 
2006). Structural properties of the bacteria are also involved in the attachment phase. In 
biofilm-development of Pseudomonas aeruginosa, flagella and type-IV pili structures as 
well as lipopolysaccharides are involved in the initial phase (O'Toole et al. 2000). 
Similarly, type I pili are required for E. coli biofilm development on almost any surface 
(Pratt and Kolter 1998). Twitching motility, a form of bacterial translocation over a 
surface in a liquid environment, seems to be important in early development of biofilm 
structures (Mattick 2002). Gram-positive bacteria are considered non-motile and the 
initial attachment is established by cell surface protein adhesions and extrapolymeric 
substance or extracellular polysaccharides (both abbreviated to EPS) instead of motility 
factors (Pratt and Kolter 1999).  
Following the initial rapid attachment, the cells proliferate, and the bacteria cluster 
together in microcolonies, which then mature into larger clusters if the conditions are 
suitable (Kiedrowski and Horswill 2011). This stage is considered to be an intermediate 
stage, often referred to as the accumulation stage. The biofilms then mature into a 
complex architecture of cells in multiple layers in three dimensions, with channel and 
pore structures (Stoodley et al. 2002). Due to being non-motile, gram-positive biofilms 
tend to be flatter with fewer three-dimensional features than their gram-negative 
counterparts. However, gram-positive biofilms can also form tower-like structures in 
certain conditions, for example under shear stress, such as the flow of the liquid or upon 
nutrient deprivation (Mann et al. 2009). It has also been shown that during the 
maturation stage of P. aeruginosa biofilms, more than half of the proteins are differently 
expressed or completely new in biofilm bacteria compared to their planktonic 
counterpart (Sauer et al. 2002). This is followed by irreversible attachment to the surface 
and EPS production by biofilm cells (Stoodley et al. 2002). 
1.1.1.2 Extracellular matrix production 
The EPS vary between and even within species, but mainly it has been shown to consist of 
polysaccharides, proteins and extracellular DNA (eDNA) (Steinberger and Holden 2005). 
The EPS is important for the biofilm since it provides structural stability and protection 
to the formed biofilm. It acts as a protective barrier against biocides or toxins and it 
sequesters nutrients from the environment, and therefore, is a part of the general 
bacterial strategy for persistence under extreme, non-favorable conditions (Donlan and 
Review of the literature 
17 
 
Costerton 2002). The EPS is also involved in virulence of many biofilm producing strains, 
especially in Staphylococcus spp. and Pseudomonas spp. (Jabbouri and Sadovskaya 2010).  
In P. aeruginosa and other Pseudomonas spp. the EPS mainly consists of alginate, a 
polymer of uronic acid and guluronate (O'Toole et al. 2000, Gacesa 1998). Alginate 
monomers can be arranged in various polymeric compositions with different block 
structures and degrees of O-acetylation. Due to being negatively charged and having a 
high molecular mass, the alginate EPS is viscous and well hydrated (Gacesa 1998). The 
exact function of alginate varies but clearly, it plays an important role in biofilm 
maturation and is also an important virulence factor for many phytopathogenic 
Pseudomonas spp. among other exopolysaccharides (Gacesa 1998). P. aeruginosa alginate 
and, thus, the EPS is one of the key problems in persistent infections in the lungs of cystic 
fibrosis patients (Williams et al. 2010). In E. coli biofilms, the main polysaccharide in the 
EPS is called PGA and it is encoded by the pgaABCD operon (Cerca and Jefferson 2008). 
The EPS of Staphylococcus spp. are represented by β-1,6-linked poly-N-acetyl-
glucosamine residues (PNAG) which are encoded by the icaADBC operon found in biofilm 
forming strains (Ziebuhr et al. 1999). PNAG is structurally and functionally very similar to 
the PGA of E. coli.  For Staphylococcus spp., the main virulence factors are connected to 
the ability to form biofilms, possessing the icaADBC operon and additionally to produce 
PNAG. A strain should, therefore, possess all of these to be considered pathogenic 
(Jabbouri and Sadovskaya 2010). Although it has been seen that biofilm-forming 
capacities are not essential for pathogens to cause infections, it has been shown that 
strains can change from being planktonic to biofilm formers depending on the 
surroundings and environmental circumstances (Chokr et al. 2007, O'Toole et al. 2000).  
1.1.1.3 Detachment and the spread of infection 
Biofilm development is a dynamic process and while continuously growing in size, 
individual cells or clumps of cells are also continuously detaching from the bulk. These 
detached bacteria can regain their planktonic status and move through the surrounding 
area to a new surface where a new biofilm can be formed. Three separate strategies have 
been identified for detachment of cells from a biofilm and can be divided into seeding 
dispersal (where individual cells are released), clumping dispersal (in which aggregates 
of cells are shed off the biofilm), and surface dispersal (in which the whole biofilm 
structure is moving along the surface it is adhered to) (Hall-Stoodley et al. 2004). In 
surroundings with continuous flow, i.e. water pipes or streams, blood vessels, or airways, 
the detachment is particularly clear and also best documented (Stoodley et al. 2001). 
Detachment of planktonic cells from biofilms is also one reason for the efficient spreading 
of biofilm-related infections (Hall-Stoodley and Stoodley 2005). 
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1.1.2 Resistance in biofilms 
Ability to form biofilms, in itself, does not cause pathogenicity but the virulence for 
pathogenic bacteria is increased if they form biofilms (Dethlefsen et al. 2007). It is not 
clear what the reasons for the increased resistance toward anti-biofilm treatments of 
biofilms compared to planktonic bacteria could be. However, extensive research has been 
carried out during the last decade to clarify this issue. The most widely used explanation 
to resistance is target modification by mutation or enzymatic change, or complete change 
of target (Lewis 2007). Metabolically heterogeneous populations, with aerobically 
growing cells on the outer part of the biofilms and metabolic inactivation of cells inside 
the biofilm bulk due to nutrient or oxygen deprivation can also lead to increased 
antimicrobial resistance (Fux et al. 2004, Hall-Stoodley and Stoodley 2009, Bordi and de 
Bentzmann 2011). The EPS layer has been thought to be a physical barrier and, 
subsequently, able to restrict antibiotics diffusion. It has, however, been shown that it is 
rather a limitation of nutrients that results in oxygen limited zones in the biofilm and 
show increased antimicrobial tolerance (Borriello et al. 2006). On one hand, the matrix is 
also thought to retard the penetration of the antimicrobial molecules and to result in 
extra time for the cells deeper down to express new genes and establish resistance even 
before the antimicrobial reaches them (Jefferson et al. 2005). It has, on the other hand, 
been shown that even macromolecules penetrate through thick biofilms in minutes or 
even seconds, and consequentially, the penetration might not be the cause for the lower 
susceptibility to antibiotics (Takenaka et al. 2009). In addition, dead cells inside the 
biofilm have been regarded as important to the development of antimicrobial resistance 
among biofilms; they can act as a nutrient source for the surrounding live bacteria and 
increase their metabolic activity but may also function as a dilution gradient for the 
antimicrobial per cell basis (Mai-Prochnow et al. 2004, Hall-Stoodley and Stoodley 2009). 
Cell death within a biofilm can also lead to an increased dispersal rate of surviving cells 
and thereby indirectly cause spreading of the biofilm (Mai-Prochnow et al. 2006).  
Persister cells are inactive cells within a bacteria population, planktonic or biofilm that 
are highly resistant toward antimicrobial therapies (Spoering and Lewis 2001). In a likely 
in vivo scenario, the metabolically active biofilm and planktonic cells of an infection 
would be killed by the antibiotic treatment, but leaving both planktonic and biofilm 
persisters alive (Lewis 2007). The planktonic persister cells are of no harm as they are 
effectively cleaned away by the immune system, but the biofilm persisters are encased 
within the EPS, which is non-penetrable for most of the immune cells and are thus not as 
easily removed by the immune system (Leid et al. 2002, Vuong et al. 2004). Yet, biofilms 
are not completely protected from the host defense, especially young or altered biofilms 
are not tolerant against host defense (Günther et al. 2009).  
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1.1.3 Biofilm related problems 
1.1.3.1 Clinically severe biofilm related infections 
Cystic fibrosis (CF) is a genetic disease, which is caused by a mutation in the cystic 
fibrosis transmembrane conductance regulator gene and leads to progressive 
dysfunctional secretion mainly in the respiratory system (Høiby 2011). Chronic 
colonization of the principal cystic fibrosis pathogen, Pseudomonas aeruginosa, results in 
progressive lung damage, respiratory failure and eventually death (Hall-Stoodley et al. 
2004). Even with long-term antibiotic treatments, these infections remain chronic and 
this is most probably due to formation of resistant biofilms in the lung secret (Singh et al. 
2000, Kirov et al. 2007). P. aeruginosa infections also induce immune system responses 
by the release of chemokines, cytokines and macrophage proteins related to 
inflammation. Nonetheless, instead of this being a response to eradicate the bacterial 
infection it is rather an increase in overall inflammation in the lung (Smith et al. 2002a, 
Smith et al. 2002b, Burmølle et al. 2010). In addition to Pseudomonas spp. infections, CF 
patients are more prone to S. aureus lung infections that are difficult to eradicate due to 
biofilm formation even with long-term anti-staphylococcal treatments (Goerke and Wolz 
2010). 
Otitis media is one of the most common diseases in young children; about 75% of all 
children under the age of three develop an otitis media infection at least once (Klein 
1994, Tähtinen et al. 2011). The infection can be either acute or chronic and can be 
caused by a range of different bacteria Streptococcus pneumoniae, Haemophilus 
influenzae, Moraxella catarrhalis and Pneumococcus spp. (Donlan and Costerton 2002). 
The chronic disease involves bacterial biofilm growth behind the tympanic membrane 
and in the middle ear. Antibiotic treatments are mostly used as treatment, but in the case 
of chronic infections, antibiotic treatment is usually ineffective and only contributes to 
resistant bacteria. Tympanostomy tubes are the suggested treatment for chronic 
infections, to relieve the pressure of the built-up fluids behind the eardrum and to 
increase ventilation to prevent further infections (Nguyen et al. 2010). However, the 
tubes themselves are also susceptible to biofilm attachment and make the treatment of 
the disease very troublesome (Donlan and Costerton 2002).  
1.1.3.2 IMD-related infection 
The number of indwelling medical device associated infections has risen in the last 
decades, mainly due to the increased use of IMDs that in turn depends on the advances in 
medical technology. Considering the advantages for patients acquiring a prosthetic device 
and the infection rate, which is usually low (around 1-10%) the risk is usually worth 
taking (Hall-Stoodley et al. 2004). The infection rate and the mortality risk in case of 
infection also need to be evaluated (Schinabeck and Ghannoum 2006). The material used 
in IMDs has been thoroughly investigated and the surface characteristics affecting the 
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adherence are texture, charge and hydrophobicity (Dunne 2002). It has been found that 
most materials can be colonized by biofilms; in vitro studies have shown that the order of 
the biomaterials that biofilms are prone to adhere to is: latex > silicone > PVC > Teflon > 
polyurethane > stainless steel > titanium (Dunne 2002, Gorman and Jones 2006).  
The most frequently used IMDs are urinary and central venous catheters; they also have 
among the highest infection rates (10-30% and 3-8%, respectively) (Donlan 2001, 
Schinabeck and Ghannoum 2006). Central venous catheters (CVC) are essential devices 
for treating critically and chronically ill patients but they are also target for severe 
biofilm-related infections that cause nosocomial bloodstream infections if contaminated 
(Raad and Hanna 2002). The bacteria causing the infection either originates from the 
surrounding skin at the insertion site, moving along the outer or inner surface of the 
device, or from the health care personnel performing the insertion into the blood stream 
where the bacteria can proliferate and grow biofilms on the surface of the catheter (Raad 
1998). Due to direct contact with the blood stream, the surface is conditioned with 
proteins (for example fibrinogen and fibronectin) that enhance biofilm formation on the 
catheter surface (Gorman and Jones 2006, Raad 1998). Pathogens that are the main cause 
of CVC-related infections are coagulase-negative staphylococci (CoNS - mainly 
Staphylococcus epidermidis), S. aureus, P. aeruginosa and other Pseudomonas spp., 
Burkholderia cepacia, Acinetobacter baumannii, Stenotrophomonas spp. and the fungal 
Candida spp. (Ferretti et al. 2003). 
Urinary catheters are widely used during hospitalization and in nursing homes and are 
also connected with infections due to biofilm growth on the catheter surfaces. The 
number of urinary catheter related infections has increased during the last decade, and it 
is currently the second most commonly used indwelling device and has the highest 
related infection rate (Holá et al. 2010). The low mortality risk if the catheter has to be 
removed makes them widely used regardless (Schinabeck and Ghannoum 2006). The 
bacteria can originate from the gastrointestinal tract and enter the system at the time of 
insertion of the catheter, or they can stem from exogenous sources and ascend up the 
inner lumen of the catheter (Tenke et al. 2012). The most widely isolated species found in 
biofilms on urinary catheters are Enterococcus faecalis, E. coli, CoNS, P. aeruginosa and 
Klebsiella pneumoniae as well as Candida albicans biofilms (Holá et al. 2010). 
Biofilm contamination on heart valves and pacemakers is the most problematic, with the 
high infectious rate (25-50%) and the highest mortality risk (> 25%) if removed 
(Schinabeck and Ghannoum 2006). Endocarditis can be caused by a native infection due 
to congenital heart defects, prosthetic heart valves or vascular grafts, probably due to the 
amassing of platelets and fibrin where biofilms can be assisted to attach and grow in the 
turbulent flow in the damaged tissue (Hall-Stoodley et al. 2004). The pathogens causing 
endocarditis have typically been found to be Streptococcus spp., Staphylococcus spp., 
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especially CoNS and S. aureus, gram-negative coccobacilli and fungi (Donlan and 
Costerton 2002). 
1.1.3.3 Severity of Staphylococcus spp. biofilms 
Staphylococcus spp. are the cause of two thirds of all IMD-related infections, in particular 
S. aureus and S. epidermidis (Kiedrowski and Horswill 2011). S. aureus, is an especially 
difficult pathogen that is involved in a range of infections (Götz 2002). The main problem 
with S. aureus is the availability; it colonizes the nasal cavities of up to 40% of individuals 
having the infection and from there can easily be transferred to the skin, where damages 
are not uncommon and the infection can be spread to the blood stream (Higashi and 
Sullam 2006). The occurrence of metabolic zones and phenotypic diversity in 
Staphylococcus spp. biofilms favor division of the labor among the biofilm bacteria and 
contributes to higher resistance and persistence towards anti-biofilm treatments 
(Yarwood et al. 2007, Stewart and Franklin 2008).   
1.1.3.4 Dental plaque 
Dental plaque is one of the most well-known types of biofilm growth, as they are easy to 
study both in vivo and in situ at the right conditions (Burmølle et al. 2010). They are 
multispecies communities normally living side by side with the host. However, a shift in 
the balance in the oral surrounding or within the bacterial community can lead to 
diseases for the host, like caries and periodontal diseases (Burmølle et al. 2010, 
Takahashi and Nyvad 2011). Caries has been shown to be an endogenous disease that is 
due to a shift of dominance towards acidogenic and acidtolerant bacteria while 
peridontitis and gingivitis are caused by increased levels of gram-negative organisms 
(Takahashi and Nyvad 2011, Teles et al. 2012).  
1.1.3.5 Other biofilms 
Water pipes are another source of biofilm-related problems that become contaminated 
by biofilms. From these the water is then delivered in large doses into humans, in whom 
the bacteria can cause infections if the bacteria are pathogenic. Regular water supply 
systems deal with this problem all over the world (Szewzyk et al. 2000). All water 
environments are natural habitats for many water bacteria both in planktonic and biofilm 
stages that are of no harm, but in less controlled environments pathogenic bacteria can 
also end up in the drinking water supplies and cause severe outbreaks of infections, for 
example caused by Vibrio cholerae and Salmonella typhi (Szewzyk et al. 2000). Dental unit 
water lines at dentist practices constitute such a case, where the system of narrow tubes 
used and where the water flows irregularly, is prone to be contaminated with pathogenic 
bacteria, such as P. aeruginosa, Legionella spp. and even S. aureus. This water is then 
administered directly into human bodies and can in rare cases cause infections, at least in 
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immunocompromised individuals (O'Donnell et al. 2011). An additional hazardous place 
for contaminated water appears when dealing with dialysis fluid. The water used for this 
purpose is filtered by reverse osmosis and should remove 90-100% of all organic and 
inorganic matter, bacteria and pyrogens, but in rare cases errors in the filtration has been 
known to lead to bacteria in the end product then administered into humans 
(Lonnemann 2004).  
1.1.4 Available treatments for biofilm infections 
1.1.4.1 Antimicrobials  
The first antimicrobial agent used in the purpose of treating biofilm infections was the 
cinchona tree bark infusion (Cinchona calisaya, C. officinalis and C. succirubra), during the 
17th century in South America. Later, quinine and cinchonine were isolated in 1820 and 
used against malaria (Greenwood 2008). Penicillin was discovered in 1928 by Alexander 
Fleming and came into the market in the 1940s. However, already in the 1960s, 
penicillin-resistant staphylococcal infections were recognized as a medical problem 
(Greenwood 2008). The aminoglycoside antibiotic streptomycin was discovered in 1944 
and was followed by chloramphenicol, tetracycline and macrolide antibiotics in the 
1950s. Vancomycin was discovered in 1956 and the first quinolone antibiotic, nalidixic 
acid was introduced in 1962. Later in the 1960s, the cephem antibiotics were developed 
and divided into generations according to their improved antimicrobial properties. 
Carbapenem and monobactam antibiotics were developed in the early 1980s (Saga and 
Yamaguchi 2009). Following this development, no new classes of antibiotics were 
developed until the oxazolidinone compound linezolid was launched in 2000 (Norrby 
2001). In the last couple of decades, only five new antibiotics actively in use against 
severe resistant bacteria have been approved: linezolid (in 2000), daptomycin (in 2003), 
tigecycline (in 2005), doripenem (in 2005) and the latest one, telavancin (in 2009) 
(Boucher et al. 2009, Moellering 2011). The antimicrobials available in Finland for the 
treatment of severe infections that can be related to biofilm growth are presented in 
Appendix 1.  
Antibiotics can roughly be divided into three categories based on the targets of their 
mechanism of action. There are antibiotics that act on the biosynthesis of the cell wall, 
interfere with the protein biosynthesis and block DNA replication and repair (Walsh 
2003). The first group is mainly represented by the beta-lactams; the penicillin and the 
cephalosporin compounds. The cell walls differ largely between gram-positive and gram-
negative bacteria and, thus, the effect of the antibiotics also varies (Koebnik et al. 2000). 
Many antibiotic features related to cell wall synthesis are connected to the assembly and 
cross linking of the peptidoglycan layer, which is thicker and more multilayered in gram-
positive bacteria (Walsh 2003). The second group consists of compounds that are able to 
interfere with the protein synthesis pathway of the bacteria; macrolides, 
chloramphenicol, tetracycline, aminoglycosides are a few examples (Schlünzen et al. 
Review of the literature 
23 
 
2001, Bulkley et al. 2010, Dunkle et al. 2010). Quinolone antibiotics are representatives of 
the third group of antibiotics, because their antimicrobial effect originates from the 
inhibition of DNA gyrase and topoisomerase IV, which are both type II bacterial 
topoisomerase enzymes that catalyze double strand DNA breakages in the bacteria (Chai 
et al. 2011). About half of the antimicrobial drugs on the market, those that have been 
used for a long time as well as those recently developed, are of natural origin or semi-
synthesized, based on a natural origin structure. Thus, nature is still the major source for 
finding novel antimicrobial agents (Newman and Cragg 2012).  
Most of the antibiotic compounds on the market are developed for planktonic bacteria. 
There are some promising agents with anti-biofilm activity that could be considered for 
drug development but are still in an early stage of development, mostly preclinical in vitro 
or in vivo studies (Moellering 2011). The cell membrane damaging porphyrin derivative 
XF-73 is one, and it has recently been shown to have anti-biofilm activity at low 
concentration levels (Ooi et al. 2010).  
1.1.4.2 Available treatments of Staphylococcus spp. biofilm infections  
There are not that many available drugs used for treatment of Staphylococcus spp. biofilm 
infections and most of the available ones have to be used as combination therapies. To 
prevent biofilm infections new materials that resist biofilm colonization are being 
developed (Lynch and Robertson 2008). Trials with medical devices emitting acoustic 
waves (Hazan et al. 2006), electric current (van der Borden et al. 2004) or pulsed 
ultrasound (Ensing et al. 2006) have been carried out on various materials (Lynch and 
Robertson 2008). Removal of the indwelling medical device, if possible, is often the best 
treatment if the infection is IMD-related (Schinabeck and Ghannoum 2006). In some 
cases, such as heart prosthetic devices, artificial joints or if the patient is not stable 
enough to undergo surgical procedures, this is not an option and there is need for 
effective anti-biofilm chemotherapies (Trampuz and Zimmerli 2006, Kiedrowski and 
Horswill 2011). Most often the treatments then required are extensive or even life-long. 
Antibiotic lock-therapies have been developed for prophylactic settings, lipopeptides and 
lipoglycopeptides have shown to be promising for use in these prophylactic methods 
(LaPlante and Mermel 2007).  
Dalbavancin is a lipoglycopeptide used against catheter related infections caused by most 
gram-negative pathogens, including many MRSA strains (Raad et al. 2005). It has a very 
long half-life time and can be dosed intravenously once a week, which is cost saving and 
more convenient for the patient (Billeter et al. 2008). Daptomycin is a lipopeptide 
clinically used against severe infections mostly caused by gram-positive bacteria biofilms, 
for example bacteremia and endocarditis (Rehm et al. 2008, Cervera et al. 2009). 
Linezolid is the only oxazolidinone compound approved for clinical use (Ford et al. 2001). 
It has shown promising results during in vitro (Raad et al. 2007, Smith et al. 2009, Leite et 
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al. 2011a), in vivo (Oramas-Shirey et al. 2001) and clinical studies (Gómez et al. 2011) 
against various kinds of Staphylococcus spp. biofilm infections, including prostethic 
device associated. However, there is also evidence for linezolid-resistant Staphylococcus 
spp. strains isolated clinically as being effective (Dandache et al. 2009). Rifampicin has 
shown to be very active in vitro (Leite et al. 2011a) and in vivo against a variety of biofilm 
associated implant infections, in addition to showing promising results in clinical studies 
(Zimmerli et al. 1998). Due to the risk of resistance, rifampicin is always administered 
together with another antimicrobial, for example daptomycin (John et al. 2009), linezolid 
(Baldoni et al. 2009), tetracyclines (Rose and Poppens 2009) or dispersing agents, such as 
N-acetyl cysteine (Leite et al. 2011b). Tetracyclines, which include tetracycline, 
minocycline, doxycycline and the newest tigecycline, are mostly used for prevention of 
biofilm growth on catheters (Zhanel et al. 2004). Tigecycline has shown promising 
activity against gram-positive biofilms in vivo (Yin et al. 2005) and in vitro (Cafiso et al. 
2010). Tigecycline together with vancomycin or rifampicin showed even an increased 
effect (Rose and Poppens 2009). Vancomycin is a glycopeptide that has shown in vivo and 
in vitro effect alone but is usually used in combination therapies with fosfomycin, 
rifampicin or tetracyclines against severe biofilm infections (Rose and Poppens 2009, 
Tang et al. 2011, Aybar et al. 2012). Unfortunately, resistance towards vancomycin has 
also been seen both in vitro and in clinical infections (Graninger et al. 2002, Antunes et al. 
2011). 
1.2 Assay development in antimicrobial drug discovery 
1.2.1 Target identification and validation 
In the search for novel drug compounds, the target for the desired pathological defect has 
to be identified (Zheng et al. 2006). Choosing a target is of great importance, as most of 
the drug failures are in the end probably due to a too vaguely chosen target for a drug 
candidate.  The compound is then either ineffective or is proven unsafe (Brötz-Oesterhelt 
and Sass 2010). The targets can roughly be divided into genetic targets, where the goal is 
to find a drug exclusively targeting a disease associated gene or gene product, and 
mechanistic targets, where the drug is affecting a single molecular mechanism related to 
the course of the target disease (Sams-Dodd 2005). This, of course, requires more 
detailed information about the genetics and the mechanisms behind disease releasing 
and proceeding factors (Sams-Dodd 2005). In the 1990s, the antimicrobial drug discovery 
process was changed from targeting the phenotype of the bacteria into targeting the 
infection (Brown and Wright 2005). The ideal target displays well characterized 
functions and is conserved in significant pathogens as well as absent in humans (Brown 
and Wright 2005). It is, as well, of crucial importance for the target organism to be able to 
be handled in Petri dishes or micro well plates. The daunting problem of resistance that is 
evolving constantly would need completely new targets and active components targeting 
them, instead of moderately change the structure and quickly develop inactivation 
mechanisms and thus, resistance (Gwynn et al. 2010). The more unknown aspects there 
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are in the development process; the higher the risk of failure is. Therefore, there is less 
interest in investments. In fact, since the 1970s, only two new classes of antimicrobials 
have been developed and have reached the market; linezolid, an oxazolidinone compound 
(launched in 2000) and daptomycin, a lipopetide (launched in 2003) (Newman and Cragg 
2012). However, the classical way of introducing new active compounds by improving old 
ones with reduced efficiency has given rise to important structures active against 
resistant organisms, for instance, rifampicin from rifamycin, and the semi-synthetic 
penicillins and the cephalosporins from penicillin (Chopra et al. 2002). There are almost 
30 compounds in clinical trials for treatment of various bacterial infectious diseases 
pending for both FDA and EMA approvals. Most of the compounds are semi-synthetic 
derivatives and some are novel natural structures produced by microbes belonging to 
existing antimicrobial classes (Mishra and Tiwari 2011). 
Many of the antimicrobial drug compounds on the market have been found to be active 
without the knowledge of the exact target or mechanism they act on from whole-cell 
screens (Baltz 2007). This strategy has re-emerged due to lack of activity on whole-cells 
for the active hits in these specific target based screenings (Gwynn et al. 2010). In this 
way, new active agents with unpredicted mechanisms on microbial whole-cell targets can 
be found, as well as being able to identify new mechanistic targets (Gwynn et al. 2010). 
1.2.2 Screening toward lead identification 
When a reliable target has been found, a suitable assay has to be chosen to be used in the 
screening for compounds against the target, and the first major choice to make is between 
using either a biochemical or a cell-based assay (Macarrón and Hertzberg 2002). 
Biochemical assays are in vitro based and have been the most frequently used in high 
throughput screening (HTS). The biochemical assays used in HTS today are very specific 
and easy to use. The most frequently used assays are so called mix-and-read assays with a 
relatively simple experimental procedure and an end point measurement based on 
absorbance, fluorescence, luminescence, optical, or scintillation readouts (Macarrón and 
Hertzberg 2011). Cell-based assays are one of the most dynamic area of modern HTS and 
they have evolved into the more physiological choice of assay that rather targets a 
pathway in the cell with complete regulatory system and feedback control, instead of just 
aiming for a single molecular target as in a biochemical approach (An and Tolliday 2010). 
Genomics has played an important role in the development of both cell based targets and 
screening assays (Johnston 2002).   
The end point readings for biochemical and cell-based assays are based on a variety of 
detection technologies and can be divided into a single measurement per well and 
multiple measurements per well (An and Tolliday 2010). The single well measurements 
includes fluorescence, luminescence and spectrophotometric methods, with fluorescence 
based assays being the most widely used, with a wide variety of fluorescent labeled 
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molecules (Gribbon and Sewing 2003). High-content screening (HCS) is a generic name 
for using any technique to measure multiple parameters per sample well (Kümmel et al. 
2010).  
1.2.2.1 Assay development and optimization 
The quality of the screening in an HTS process has to be particularly reliable compared to 
smaller scale screening areas. Variability has to be kept low and the signal to background 
(S/B) has to be as high as possible to gain optimal screening results throughout the whole 
screening campaign (Macarrón and Hertzberg 2002). To avoid the number of factors to 
optimize rising to impossible levels, knowledge about the system used is of great 
importance (An and Tolliday 2010). The reagents and consumables used in the assay 
have to stay stable during the whole process. The effect of the compound solvent, usually 
dimethyl sulfoxide (DMSO), has to be evaluated for a possible effect on the assay 
performance (Macarrón and Hertzberg 2002). Determination of cell density, incubation 
time with the compounds and exposure time with the probe are essential factors for 
optimization of the performance for cell-based assays (An and Tolliday 2010). 
Miniaturization lowers the costs and consumables. Today the typical working platform 
for HTS is 384 micro well plates, but 96 well plates as well as 1535 well plates and even 
up to 3456 well plates are in use. The use of reagents is drastically lowered when using 
smaller wells, 96 well plates require 100-200 µl per well, 384 well plates 30-100 µl, 1536 
well plates 2.5-10 µl and 3456 well plates require only 1-2 µl per well (Mayr and Bojanic 
2009). The increased number of compounds that can be screened per day follows the 
assay miniaturization. In addition, the time used for the steps of the screening assay has 
to be thoroughly optimized in order to make the screening campaigns time-effective. 
Costs, along with the time and statistical robustness are the three pillars in which a 
successful HTS process relies on (Mayr and Bojanic 2009).  
In an automated assay, the performance is improved by decreasing variability and higher 
throughput of screened compounds. The automation of assays allows saving labor, 
consumables and reagents due to higher accuracy of the performance (Tammela 2004). 
For automation of a HTS system, instrumentation for routine liquid-handling, robotic 
plate handling and sensitive detection is required. If the used assay requires more 
specialized instrumentation, there can be need of washing stations, incubators, plate 
sealer or piercer (Thiericke 2003). Modern screening systems are mostly integrated into 
large independent facilities with control systems that are not necessarily in need of 
constant human supervision (Michael et al. 2008).  
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1.2.2.2 The screening process 
The initial source of drug compounds used to be nature and still almost half of all newly 
developed drugs are natural or based on natural scaffolds (Newman and Cragg 2012). 
The scaffold of chemical structures produced by nature has not and probably cannot be 
mimicked by synthetic concepts (von Nussbaum et al. 2006). The major source of drugs 
based on natural products is plants, followed by animals, bacteria and fungi, and about 
30% of the total number of drugs consists of semi-synthetic analogues or derivatives 
(Harvey 2008). Despite the fact that plants are the major source of natural based drugs 
there are still no antimicrobial drugs on the market that are plant based (Gibbons 2005, 
Newman and Cragg 2012). About 70% of all natural compounds from bacterial sources 
originate from Streptomyces spp. and myxobacteria (Grabley and Sattler 2003). However, 
marine organisms are significantly more taxonomically diverse than terrestrial 
counterparts and possess completely new, highly complex structures that may possibly 
have potential to be active against various drug targets. So far, they are not as thoroughly 
investigated, but there is an increasing trend toward more interest in compounds from 
marine sources (Leal et al. 2012).  
Combinatorial chemistry is a fast way to synthesize large scale libraries from known 
structures. It was revolutionary at its introduction in the 1990s and has been re-
established as a widely used technique within all steps of modern drug discovery from 
high throughput screening campaigns to in vitro and in vivo drug metabolism studies and 
pharmacokinetic assays (Kennedy et al. 2008).  
Chemoinformatics is a research area, which deals with the application of informatics 
methods to solve chemical or biological issues. It can be used for effectively designing the 
optimal library to be synthesized by combinatorial chemistry, which can then be used for 
HTS or to establish the relationships between structure and biological activity, among 
other problems. In a primary screening, the library used should cover a wide range of 
physicochemical properties and all the compounds should preferably be drug-like to 
make the search more biologically relevant. In targeted library design, the opposite needs 
to be utilized, because similarity of the compounds in the library is emphasized instead 
(Matter 2003, Engel 2006). Virtual screening is a complement to HTS where large 
libraries of compounds (even those that do not physically exist) can be tested using a 
variety of selection criteria. This approach mainly ranks the compounds before the in 
vitro testing of the compounds to prioritize the testing of the candidates most likely to be 
positive hits. This kind of in silico screening has been extensively applied for ligand-based 
targets where large databases are searched. Approaches typical for ligand-based virtual 
screening include pharmacophore, machine learning and similarity methods (Engel 2006, 
Dürig et al. 2010). 
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1.2.2.3 From hits to leads to drugs 
A hit in a screening campaign is a compound showing activity against the target used at 
relatively low molarities, depending on the target (Wunberg et al. 2006). For the hit 
compound to become considered as a lead compound, it has to display other properties 
beyond potency, for instance some degree of selectivity and specific binding. Beneficial 
ADME-Tox properties (absorption, distribution, metabolism, excretion and toxicity) 
similarly play an important role in deciding the relevance of a hit compound. If a large 
number of hits are found in a screening, the accessibility of the compounds and how 
easily synthesizable they are can be of importance in the selection (Wunberg et al. 2006). 
Certain physicochemical properties in order to determine whether molecules are more 
likely to behave as lead compounds were introduced by Lipinski et al. (2001) (Table 1), 
with the rules of five and specified by Teague et al. (1999) to lead-likeness properties 
(MW < 350 Da, logP < 3) in the late 1990s. Lipinski’s fifth rule, however, excludes the four 
first rules if the compound has a natural origin, because they do not apply to them and 
would require their own guidelines (Newman and Cragg 2012). The scenario seems to be 
truly complex as it has been shown in a study of effective natural products drugs that half 
of the compounds fell well within the rules of five, while the other half violated them 
radically (Ganesan 2008, Newman and Cragg 2012). Most of the available antimicrobial 
drug compounds are also exceptions to the rules of five, since they are usually larger and 
more hydrophilic than other drug classes (Payne et al. 2007, O'Shea and Moser 2008). 
Table 1. Rule of five properties for molecules in drug discovery and how the natural products and 
the antimicrobials are exceptions to these rules.  
 Rules of five  
(Lead-likeness) 
Natural products  
 
Antimicrobials  
 
Molecular weight < 500 Da (< 350 Da) ca 240-1600 Da Usually < 600 Da, up to 
1 kDa 
Log P < 5 (< 3) Usually < 5 Usually < 5 
H-bond donors  < 5 Usually < 5 up to 20 Usually < 5, up to 20 
H-bond acceptors  < 10  Usually ca 10, up to 30 Usually ca 10, up to 40 
References (Lipinski et al. 2001, 
Teague et al. 1999) 
(Ganesan 2008) (O'Shea and Moser 
2008) 
For a compound to proceed in the drug development process, it also needs to have drug-
like properties, such as good solubility, membrane permeability, proper half-life and 
pharmacophore properties to interact specifically with the target. For natural products, 
these properties are not always fulfilled. However, a natural product might more easily 
enter into a cell than a synthetic structure, but the natural compound might also be more 
susceptible to efflux pumps and other clearance methods (Ganesan 2008). Chemical 
optimization of the molecules can be carried out either at the lead discovery stage, by 
synthesizing analogues that possess improved properties to better fit the lead search, or 
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the discovered lead molecules can be optimized to have improved drug-likeness, in other 
words, drug optimization (Proudfoot 2002). For natural products, this can be a difficult 
task and often the compound is in its original form throughout the drug development 
(Ganesan 2008). This process can be carried out the other way around: first demanding 
the criteria and then searching for candidates. This probably increases the chance of 
finding positive hits within the scope of the search, but reduces the likelihood of 
discovering new drug classes (Muegge 2003). The design of natural product structures 
has had a biosynthetic purpose for the producer organism and is, hence, probably 
advantageous over synthetic molecules in bioactivity (Mishra and Tiwari 2011). 
1.2.2.4 Statistical tools 
Signal-to-noise (S/N) is a parameter distinguishing the real signal from the background 
noise (Macarrón and Hertzberg 2002). Another parameter used is signal to background 
which only distinguishes the maximal signal from the minimal signal, but no variation is 
taken into account. Signal-to-background (S/B) ratio is signal and equipment dependent 
and can be said to only be used within one assay to prove good plate-to-plate and day-to-
day repeatability (Macarrón and Hertzberg 2002). This means that neither S/N nor S/B 
takes the variability and dynamic range of the signal simultaneously into account (Zhang 
et al. 1999).  
The measuring of the relative variability of the signal or the background signal coefficient 
of variation (CV) is a useful parameter. The parameter indicates the stability and 
precision of the assay behavior, such as liquid handling and detection instrumentation 
(Macarrón and Hertzberg 2002).  
The separation band is defined by the difference between the positive controls and the 
negative controls and measures the dynamic range of the assay (Figure 2) (Zhang et al. 
1999). The Z’-factor is a dimensionless parameter able for comparison across methods. 
The parameter is defined as the ratio of the separation band to the signal range of the 
assay. In other words, it shows the relative separation of the maximal signal values from 
the background values (Zhang et al. 1999). It has a range from 0 to 1, where Z’=0 
indicates the maximal and minimal signals overlap and Z’=1 indicates the ideal assay with 
infinite separation (Zhang et al. 1999). Usually, Z’>0.5 is considered to designate a 
properly performing assay. However, for cell based assay Z’≥0.3-0.4 is considered to be 
acceptable (Merten 2010). There is a correlation between Z’, S/B and CV: a Z’ of 0.4 is 
equivalent to a CV of 10% and S/B of 3. A lower variation, accordingly, allows lower S/B, 
but due to CV, which hardly ever falls below 5%, an S/B of 2 is required to have an 
acceptable result for Z’ (Macarrón and Hertzberg 2011). Z’ should be used during 
validation of the screening assay but also throughout the screening process to be able to 
detect failed plates and exclude the results within them to avoid false results (Macarrón 
and Hertzberg 2002). To make a distinction between the tested compounds that do not 
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have any effect and those that show activity, a threshold value or a hit limit has to be set 
(Mayr and Bojanic 2009). In large screening campaigns, unbiased libraries of compounds 
are usually used and most of these are expected to show low or no activity and the 
activity histogram is usually close to be normally distributed. The hit limit can then be 
defined as SDs away from the mean of the control signal, 3 x SD is the most common 
choice (Zhang et al. 1999). However, the hit limit can also be empirically chosen 
depending on the assay, for example 50% activity, to retrieve reasonable numbers of hits 
to be handled in secondary screening assays. The determination of the hit limit is of 
utmost importance in order to end up with the best ratio of false negative and false 
positive results. The further away from the mean of the control the hit limit is set; the 
lower the risk of false positives. However, the risk of false negatives increases (Zhang et 
al. 1999). Compounds found close to the hit limit have some probability to cross over if 
retested and in the ideal situation very few points are found close to the hit limit; they are 
either clearly positive or clearly negative. This can be achieved by increasing the quality 
of the assay by lowering the variability (Zhang et al. 1999).  
 
Figure 2. A schematic view of a model signal window and the equations of the statistical 
parameters. The values of the parameters are calculated from the Relative Measurement Units of 
the points.  
1.2.3 Antimicrobial screening assays  
There are many available methods that are standardized for testing compounds for 
antimicrobial activity against planktonic bacteria. These include: disk diffusion, agar 
dilution, antibiotic gradient disks, and broth micro dilution; they are appropriately 
optimized and have been used for decades (Jorgensen 1993, Amsler et al. 2010). Broth 
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micro dilution is the most widely used due to its simplicity and suitability for most 
bacterial strains (Jorgensen 1993, Rahman et al. 2004). The end point can be visualized or 
measured spectrophotometrically or using a colorimetric redox indicator (Rahman et al. 
2004).  
The corresponding situation is different when it comes to anti-biofilm screening. There 
are hardly any standardized methods for studying biofilms and especially not for 
screening for substances with anti-biofilm activity (Pettit et al. 2009). One assay for 
growing and treating a P. aeruginosa biofilm in a high throughput screening setting called 
the MBEC™ Assay has been standardized by the American Society for Testing and 
Materials (ASTM International 2011). Similarly, a few anti-biofilm screening assays have 
been developed using the most common biofilm forming species of P. aeruginosa, E. coli, 
S. aureus and S. epidermidis. These methods are mostly based on the 96 micro well plate 
format, with one exception being an anti-biofilm screening against P. aeruginosa biofilms 
in 384 well plates, using a BacTiter Glo based assay (Junker and Clardy 2007). Other 
methods use turbidity measurements (Ceri et al. 1999), crystal violet (Stepanovic et al. 
2000), crystal violet together with 5-cyano-2,3-ditolyl tetrazolium chloride (CTC) and log 
reduction (Pitts et al. 2003), or resazurin (Pettit et al. 2005, Pettit et al. 2009, Mariscal et 
al. 2009). Other staining methods have been developed for detecting biofilms or effects 
on biofilms, but not for screening purposes. Tetrazolium salts, such as XTT (2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) are reduced by 
metabolic activity to a colored formazan product that can be visually or 
spectrophotometrically detected, which measures cell viability in the biofilms (Adam et 
al. 2002, Peeters et al. 2008). Another viability probe is fluorescein diacetate, which is 
converted into highly fluorescent fluorescein by esterases found both intra- and 
extracellularly (Honraet and Nelis 2006). SYTO 9 has been widely used in microscopy 
approaches for detecting living cells, both eukaryotic and prokaryotic in a combination 
with a probe staining only the dead cells, i.e. a LIVE/DEAD staining kit (Karthikeyan and 
Beveridge 2002, Jefferson et al. 2005). SYTO 9 penetrates the cell membranes and binds 
to the DNA of living and dead cells, causing a green fluorescent signal (Honraet and Nelis 
2006). 
So far, no method has been developed that can measure all features desirable for anti-
biofilm studies. The existing methods measure only one feature each. Viability can be 
measured by resazurin (O'Brien et al. 2000), total biomass can be measured by crystal 
violet (Christensen et al. 1985) and the effect on the EPS layer can be measured by wheat 
germ agglutinin linked to an Alexa fluorophore (Burton et al. 2007), or 1,9-dimethyl 
methylene blue (DMMB) (Toté et al. 2009). 
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Table 2. Methods for studying biofilms and effect of compounds on biofilms. 
Staining probe Detection 
method 
Measured 
feature  
Assay 
format 
Key references 
 Plate count CFU Agar plates  
 Turbidity growth 96 mwp, 
pinlids 
Ceri et al. 1999 
Safranin or 
trypan blue stains 
Visual detection biomass Test tube Christensen et al. 1982 
Crystal violet Visual detection, 
absorbance 
biomass Tube test, 
96-mwp 
Christensen et al. 1985, 
Stepanovic et al. 2000 
Tetrazolium salts 
(XTT, MTT, etc) 
Absorbance viability 96-mwp Adam et al. 2002, 
Peeters et al. 2008 
Fluorescein 
diacetate 
Fluorescence viability Flow system Honraet and Nelis 
2006 
Resazurin Fluorescence, 
absorbance 
viability 96-mwp O'Brien et al. 2000, 
Mariscal et al. 2009, 
Pettit et al. 2005 
SYTO 9 Fluorescence, 
microscopy 
viable cells Flow system, 
96-mwp 
Honraet and Nelis 
2006, Jefferson et al. 
2005 
BacTiter Glo Luminescence Attachment 
vs 
detachment 
384-mwp Junker and Clardy 2007 
WGA-Alexa 
fluorophore 
Fluorescence, 
microscopy 
EPS 96-mwp Burton et al. 2007 
Dimethyl 
methylene blue 
(DMMB)  
Absorbance  EPS 96-mwp Toté et al. 2009 
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2 Aims of the study 
Most of the methods used in antimicrobial research have been developed for planktonic 
bacteria. However, bacteria in natural environments mainly exist in biofilm form and 
biofilms are more prone to cause severe infections than their planktonic counterparts. 
Additionally, since the infections caused by biofilms are often very difficult to treat, there 
is a need to find new active anti-biofilm agents. The aim of this research project has been 
to fill the void of screening assays that can be applied for the search of novel anti-biofilm 
compounds, using Staphylococcus aureus as a model strain. What distinguishes this study 
is the embraced strategy, as it is aimed to develop a platform of cell-based assays, which 
could measure the essential features of bacterial biofilms, most relevant from a drug 
discovery perspective. In this approach, the focus is on building high-information, multi-
signal, screening-based assays that could permit the identification of true anti-biofilm 
hits. 
The specific aims of the study were to: 
- optimize the performance of the biomass based crystal violet assay with statistical 
tools, to be used for automated anti-biofilm screening of a natural compounds library 
(I) 
- evaluate the use of the resazurin probe for viability detection on a fast anti-biofilm 
screening of a natural and naturally-derived chemical library (II) 
- improve the anti-biofilm assay platform by addition of a third assay based on specific 
binding of a WGA-probe to the matrix and establish a platform of assays for screening 
of libraries against bacterial biofilms by targeting viability, biomass and the EPS-layer 
(III)  
- develop an additional method using capillary electrochromatography (CEC) for 
immobilizing biofilm-forming bacteria and studying anti-biofilm effects of compounds 
(IV) 
- apply the three optimized assays in a validatory antimicrobial and anti-biofilm 
screening using a library of cinchona alkaloids (V) 
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3 Materials and methods 
3.1 Materials and equipment 
Tryptic soy broth (TSB) and tryptic soy agar (TSA) were purchased from Fluka 
Biochemika (Buchs, Switzerland). Crystal violet (2.3% w/v), resazurin, dimethylsulfoxide 
(DMSO), 3-aminopropyltriethoxysilane (APTES), poly-L-lysine and Mueller-Hinton broth 
were from Sigma–Aldrich (Steinheim, Germany). Wheat germ agglutinin-Alexa 488 and 
LIVE/DEAD® BacLightTM were from Molecular Probes, Inc. (Eugene, Oregon, USA). 
Phosphate buffered saline (PBS) was from Lonza (Verviers, Belgium). Hydrochloric acid 
was from Oy FF-Chemicals Ab (Yli-Ii, Finland). All the antibiotics used; penicillin G, 
ciprofloxacin, fusidic acid, methicillin, oxacillin, polymyxin B, rifampicin, streptomycin, 
and vancomycin were from Sigma–Aldrich (Steinheim, Germany).  
The 96-well polystyrene micro well plates with Nunclon™ Δ surface were from Nunc 
(Roskilde, Denmark). The uncoated fused-silica capillaries were from Composite Metal 
Services Ltd. (Worcestershire, UK). The Varioskan Flash Multimode Plate Reader and the 
Multidrop® Combi dispenser were from Thermo Fisher Scientific Oy (Vantaa, Finland). 
The Biomek® 3000 liquid handling workstation was from Beckman Coulter, Inc. 
(Fullerton, California, USA). The Hewlett-Packard 3DCE system was from Agilent 
(Waldbronn, Germany). The Lauda Ecoline Re-104 water bath was from Lauda (Lauda-
Königshofen, Germany). The Nanoscope IIIa scanning probe microscope equipped with a 
J-scanner was from Digital Instruments, Inc. (Santa Barbara, California, USA) and was 
used for imaging the sample surfaces. The silicon cantilevers (model NSC15/NoAl were 
from MicroMasch (Tallinn, Estonia). The AxioVert 200M fluorescence microscope was 
from Carl Zeiss MicroImaging GmbH (Munich, Germany). 
3.1.1 Compound libraries 
A chemical compound library of 686 compounds was provided by Professor Thomas 
Erker at the University of Vienna, Austria. The cinchona alkaloid library consisting of 24 
compounds was provided by Professor Reko Leino at the Laboratory of Organic 
Chemistry, Åbo Akademi University, Finland. The library of 86 bacterial extracts from the 
Arctic Microbe culture collection (ARMI) was provided by Dr. Minna Männistö at the 
Finnish Forest Research Institute (Metla), Rovaniemi, Finland. An in-house collection of 
123 natural compounds was also used, Department of Biosciences, Åbo Akademi 
University, Finland.  
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3.1.2 Bacterial strains (I-V) 
The bacteria strains Staphylococcus aureus ATCC 25923, Staphylococcus aureus Newman, 
Staphylococcus epidermidis ATCC 12228, Staphylococcus epidermidis RP62A (ATCC 
35984) and Escherichia coli XL1 Blue were obtained from the Faculty of Pharmacy and 
the Faculty of Veterinary Medicine, University of Helsinki, Finland.  
3.2 Methods 
3.2.1 Bacterial culture (I-V) 
All strains were stored in -70°C in tryptic soy broth (TSB) containing 20% glycerol. Fresh 
cultures were started from the glycerol stocks and pre-cultured in TSB over night in 37°C 
with 220 rpm shaking. The liquid cultures were prepared by diluting the pre-cultures 
1000 times (S. aureus-strains, E. coli) or 100 times (S. epidermidis) in fresh TSB and under 
aerobic conditions at 37°C and 200 rpm to reach exponential growth. The concentration 
was routinely estimated by spectrophotometric turbidity measurement at 595 nm using a 
Varioskan Multimode Plate Reader. For determination of the concentrations, the cultures 
were serially diluted and plated on tryptic soy agar (TSA). The bacterial concentration 
was established as colony forming units per milliliter (CFU/ml). 
3.2.2 Optimization of biofilm formation conditions (I-V) 
Biofilms were always formed from fresh cultures, by diluting the exponentially grown 
culture to be approximately 106 CFU/ml. The biofilms were grown in sterile 96-microwell 
titer plates by dispensing 200 µl of the diluted bacterial culture per well. Biofilms were 
formed in 37°C, 200 rpm for 18 h. These conditions were optimized by testing various 
dilutions of the culture (from 103 to 108 CFU/ml) and incubation times (from 4 to 24 h). 
Crystal violet was used for the endpoint measurement. 
3.2.3 Cryopreservation of S. aureus biofilms (I) 
To store ready-made biofilms containing plates, 96-well polystyrene micro well plates 
with biofilms were prepared as described in 3.2.2. After 18 h of biofilm formation in 
optimal assay conditions, the planktonic suspension was removed and the plates 
containing biofilms were sealed and immediately frozen at −20°C for a period of up to 7 
days. The bacterial concentration was compared in fresh and frozen plates made from the 
same culture by detaching the biofilms mechanically, diluting the bacteria in fresh TSB 
and performing counts on TSA plates. After 7 days, biofilm formation determined by 
crystal violet staining was also compared with freshly prepared biofilms. Similarly, the 
ability of the preserved biofilms to perform in a screening assay using model compounds 
was estimated and compared with freshly prepared biofilms. Briefly, plates were 
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removed from the deep-freezer 1 h prior to the experiments and were defrosted at room 
temperature. The selected compounds were added to the plates with fresh TSB and 
incubation was carried out in the same conditions used for screening (37 °C, 200 rpm, 2 
h). The plates were stained with crystal violet stain assay. 
3.2.4 Automation of the crystal violet staining protocol (I) 
First, a manual performance of the crystal violet staining assay was optimized. The 
biofilms formed in a 96-well plate were washed once with 200 µl of MQ-water prior to 
the addition of 190 µl of the crystal violet solution. The plate was incubated for 5 minutes 
at room temperature (RT). The stain was removed and the plate was washed twice with 
MQ-water. After the last washing step the plate was left to dry and the remaining stain 
was dissolved in 96% ethanol. Absorbance was spectrophotometrically measured at 595 
nm.  
Automation of the assay was conducted by using the Multidrop Combi dispenser for 
sterile dispensing of the bacteria onto 96-well plates with an addition of the crystal violet 
stain. The Biomek® 3000 liquid handling workstation was used for the washing steps. The 
same staining protocol as was used in the manual method was utilized, except for an 
additional washing step after the removal of the stain. The programming of the 
dispensing and aspiration steps was optimized and the optimal settings were used for the 
experiments (dispensing speed 150 μl/s, aspiration steps conducted from the edge of the 
well bottom).  
3.2.5 Optimization of the resazurin staining assay (II) 
The resazurin stain was prepared in sterile water and kept sterile for further usage at 
+4°C during one month. For the staining procedure, the culture media and non-adhered 
cells were removed from the mature biofilms and replaced by resazurin diluted in PBS. 
Four concentrations of the stain were initially tested, ranging from 2 µM to 2 mM. The 
plates were incubated in darkness and at RT during six different ranges of time (15, 20, 
30, 60, 120 and 240 minutes). As a final step, the fluorescence was measured using an 
excitation filter of 560 nm and an emission filter of 590 nm. 
The relation between the fluorescent signal generated by the reduced resazurin and 
bacterial concentrations in the wells was studied for both bacterial suspensions and 
biofilms. In the first case, dilutions of an exponential phase bacteria culture (from 2.80 x 
104 to 2.80 x 108 CFU/ml) were prepared in 96-well micro titer plates. Resazurin stain 
was added (20 µM) directly to the wells and the plates were incubated in darkness, RT for 
20 minutes followed by the measurement of fluorescence as indicated above. In the 
second case, different biofilm concentrations were achieved by incubating suspensions 
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on the plate during different time periods ranging from 1 hour to 24 hours. For the 
staining, planktonic bacteria were removed and resazurin (20 µM) added as described 
above. To measure actual concentrations in the wells, biofilms from replicate wells were 
scraped and plated on TSA, as indicated before.  
3.2.6 Wheat germ agglutinin staining (III) 
The wheat germ agglutinin probe was kept in ‒20°C in 1 mg/ml stock solutions and 
always kept from redundant light exposure. The protocol used was according to the 
original description of the method by Burton et al. (2007). Briefly, the planktonic 
suspension was removed from the wells and the wells were washed once with sterile 
PBS. The stain was added (5 µg/ml) and the plate was incubated in darkness, +4°C for 
two hours. Unbound stain was washed off by washing the wells with 200µl of PBS three 
times, followed by air drying the plate for 15 minutes at RT. The bound stain was 
dissolved in 33% acetic acid and sonicated twice with an incubation period of one hour in 
between to detach the bound mass from the wells. The fluorescence was then measured 
at a Varioskan Multimode plate reader.  
3.2.7 Capillary electrochromatography (IV) 
Phosphate and acetate buffers (8 mM) were used as background electrolyte (BGE) 
solutions. Bacterial suspensions in BGE were prepared by centrifuging TSB suspensions 
at 2500g for 5 min, re-suspending the bacterial pellet in BGE, with the centrifugation step 
repeated twice. 
The electrophoretic measurements were carried out with a Hewlett-Packard 3DCE 
system equipped with a diode array detector and an air-thermostating capillary. The 
capillary was coated with poly-L-lysine (1:10 v/v diluted in BGE) by flushing for 30 min 
with a sterile phosphate saline buffer, for 30 min with poly-L-lysine, and finally, the 
capillary was flushed once again with sterile PBS for 15 min to remove the extra poly-L-
lysine not bound to the capillary surface. Following this, the capillary was treated for 17-
20 h with bacteria. Briefly, the capillary was flushed for 30 min with S. aureus and left to 
stand filled with bacteria for 30 min. The whole 60 min treatment was repeated 17-20 
times.  
DMSO was used as EOF marker and worked as an indicator for surface charge changes 
during biofilm formation. The biofilm coated capillary was flushed for 2 min with the 
antibiotics, and then the antibiotics were left standing for 2 h. EOF was also monitored in 
the antibiotic/biofilm interaction studies by carrying out six successive runs. The 
experiments in the capillary and auto-sampler were always performed at 37°C. Before 
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every experiment, the coated capillary was flushed for 2 min with BGE. The time of the 
runs ranged from 5 to 20 min depending on the mobility of the EOF marker. 
3.2.8 Antibiotics susceptibility testing (I, IV) 
Minimal inhibitory concentrations (MIC) were established by using standard techniques 
according to the CLSI, with some modifications. To establish planktonic MIC for the 
antibiotics used, the compounds were serially diluted two-fold in plates (from 1.2x10-4 
mg/ml to 1.024 mg/ml) and with bacteria added. The plates were incubated at 37°C and 
200 rpm for 18 h and then stained using the crystal violet assay. Biofilm MIC values were 
established by adding the serially diluted antibiotics to mature biofilms and incubating in 
37°C and 200 rpm for 24 h and then stained with crystal violet. The lowest concentration 
of the antibiotics able to prevent biofilm formation (planktonic MIC) or eradicate mature 
biofilms (biofilm MIC) and causing the crystal violet signal to be lower than the hit limit, 
was determined as MIC. 
3.2.9 Screening of compound and extract libraries (I, II, V) 
All compounds of the in-house library were prepared as dry DMSO stocks (20 mM) and 
stored at ‒20°C. Aliquots were further diluted in TSB to reach a final concentration of 40 
μM and a DMSO final concentration of 0.25%. In cases of solubility problems no further 
dilution in TSB was used and maximal DMSO concentration used was 2%. The bacterial 
extracts were prepared to 30 mg/ml in dry DMSO and the final concentration tested on 
biofilms was 0.6 mg/ml. Screening was run in two different modes: prevention of biofilm 
formation and destruction of formed biofilms. In the biofilm prevention experiment, the 
compounds were added simultaneously with the bacterial suspension and were 
incubated in optimal biofilm-forming conditions (18 h, 37°C, 200 rpm). In the destruction 
mode, mature biofilms were grown for 18 h, the planktonic suspension was removed and 
replaced by fresh TSB along with the compounds and incubated in optimal biofilm-
forming conditions for 2 or 24 h.  
The effect of DMSO was established using the crystal violet assay by making two-fold 
serial dilutions to achieve final DMSO concentrations ranging from 0.001% to 20%. 
3.2.10 Visualization using atomic force microscopy (AFM) (I, IV) 
Bacterial biofilms formed on polystyrene pieces were used for AFM visualization. The 
pieces were taken from micro well plate bottoms (Nunclon™ Δ surface) and were small 
enough to fit the microscope sample area. Polystyrene pieces with biofilms formed during 
0 h and 18 h, as well as polystyrene pieces with TSB during 0 h and 18 h, were prepared. 
In 0 h samples, the bacterial suspension (106 CFU/ml) or TSB was added to the 
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polystyrene plate and then immediately removed. Following incubation, the planktonic 
suspension was removed and the plates were left to air dry for 30 min in sterile 
conditions. 
A Nanoscope IIIa scanning probe microscope equipped with a J-scanner was used for 
imaging the sample surfaces. The microscope was placed on an active vibration isolation 
table (MOD-1M; JRS Scientific Instruments, Zwillikon, Switzerland), which was further 
placed on a massive stone table to eliminate external vibrational noise. Silicon cantilevers 
(model NSC15/NoAl) were used for imaging. All images (512 × 512 pixels) were captured 
using the intermittent contact AFM mode in ambient conditions (RH = 34 ± 5%, T = 25 ± 2 
°C) without filtering. The free amplitude of the oscillating cantilever (off contact) was ca. 
60 ± 15 nm. A damping ratio (contact amplitude/free amplitude) of ca. 0.7–0.8 and a line 
frequency of 1.00 Hz was used for imaging. The Scanning Probe Image Processor (Image 
Metrology, Hørsholm, Denmark) software was used for the image analysis. 
3.2.11 Visualization using Fluorescence Microscopy (III, V) 
Mature (18 h) biofilms were imaged for viability and EPS production using Fluorescence 
Microscopy (FM). Viability imaging was undertaken with the commercial bacterial 
viability kit LIVE/DEAD® BacLightTM that contains SYTO 9 (stains viable cells green) and 
propidium iodide (stains dead cells red). Final concentrations of the probes (added as a 
mixture, 6 µl/well) were 5 µM and 30 µM, respectively. For EPS imaging, the WGA probe 
was added and incubated for 2 h at 4°C in darkness, as previously described. FM pictures 
were taken after removing the unbound dye. Images were captured with an AxioVert 
200M fluorescence microscope, using a FITC filter (SYTO 9, WGA) or a TRITC filter 
(propidium iodide).  
3.2.12 Data processing and statistical analysis (I-V) 
For characterizing the assays, plates containing positive (bacteria, maximal signal) and 
negative (TSB, minimal signal) control wells were made, so that plate-to-plate and day-to-
day variations could be established. The plate-to-plate variability was established by 
comparing the mean of the maximal signal in three plates made the same day, whilst the 
day-to-day variability was made by comparing the mean of the maximal signal of three 
plates made on separate days. In all cases, coefficients of variations of the maximal signal 
were calculated. Statistical parameters characterizing the performance of the screening 
assay were calculated and used to monitor the assay optimization process. The 
parameters signal window coefficient Z′-factor, signal-to-noise (S/N), signal-to-
background (S/B), separation band, and coefficient of variations (CV) of the signals were 
calculated using the corresponding formulae indicated below. The hit limits used in the 
screening experiments were calculated according to equation 6. In all equations, SDmin, 
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Xmin and SDmax, Xmax represent the standard deviations and means of the minimal (min) 
and maximal (max) signals, respectively.  
The Kolmogorov-Smirnov test was used to assess the signals’ binominal distribution. 
One-way ANOVA comparisons and Tukey post tests were applied to the original 
fluorescence and absorbance data points. In the case of paired comparisons, unpaired t-
test with Welch's correction was used, where p<0.05 was considered statistically 
significant. GraphPad Prism software, v. 5.0 for Mac OS (La Jolla, CA, US) was used for the 
entire span of calculations. 
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4 Results 
4.1 Optimization of biofilm formation conditions (I, IV) 
To determine the optimal conditions for S. aureus biofilm formation in 96-well micro well 
plates ten different time ranges (2 to 24 h) and six different bacterial concentrations (103 
to 108 CFU/ml) were tested and stained using the manual crystal violet assay. Previously, 
a wide variety of conditions for biofilm formation in 96-well micro well plates have been 
reported using initial bacteria concentrations from 105 to 108 CFU/ml and incubation 
times from 4 up to 24 h (Amorena et al. 1999, Stepanović et al. 2001, Giacometti et al. 
2005). The optimal biofilm formation according to statistical performance was detected 
using 106 CFU/ml as the initial bacterial concentration. At that concentration, a significant 
biofilm formation was registered when bacteria were incubated between 12 and 18 h in 
37°C and 200 rpm. For practical convenience in performing the experiments overnight, 
18 h of biofilm formation was further selected. However, biofilms also seem to survive 
longer without refreshing of nutrients in 96-micro well plates as well as in the CEC 
system (IV), as biofilms were kept in the capillary for two days after formation.  
To confirm biofilm formation in these optimal conditions, imaging experiments using 
AFM were conducted. A clean surface was obtained in the negative control wells 
indicating the absence of biofilms when incubating the plates only with TSB (Figure 2A in 
Publication I). Moreover, no biofilm was detected in samples in which bacteria were 
added and then removed immediately afterward (0 h sample). The image of the sample 
treated with bacteria for 18 h showed a homogeneous surface of round bacteria capsules 
(Figure 2B in Publication I). 
4.2 Screening assay platform (I-III) 
4.2.1 The crystal violet assay (I) 
4.2.1.1 Optimization and detection limit (I) 
The manual performance of the crystal violet staining assay was optimized by modifying 
previously published protocols (Stepanovic et al. 2000, Kolari et al. 2001). This was 
carried out in order to improve the performance without endangering the statistical 
quality of the assay.  Modifications to the protocol consisted of reducing the number of 
washings steps that were conducted: one washing before adding the stain was carried out 
instead of two, and two washing steps to remove unbound stain were undertaken instead 
of three washing steps after the staining. These modifications did not affect the statistical 
performance of the assay, as the parameters were similarly good, but they allowed for 
cutting down the time required and decreasing the labor involved in testing. Although the 
crystal violet assay has been extensively applied, the detection limit has not been 
emphasized. This is probably due to the fact that the readout signal measures both living 
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and dead cells (that together with the EPS generally is referred to as the biomass). 
However, we attempted to measure the detection limit, as it can still provide information 
on the linear dependence range of the assay. If this assay is used in combination with 
other assays, this information is relevant to understand whether the assays are able to 
quantify biofilm formation in a similar fashion. The lowest biofilm concentration resulting 
in a signal was 2x107 CFU/ml (Figure 3) which coincides well with bacterial densities 
(107 CFU/cm2) normally reached in micro plate wells (Pitts et al. 2003).  
 
Figure 3. Relation between bacterial concentration and relative absorbance units of biofilms 
stained with crystal violet. 
4.2.1.2 The crystal violet assay; manual vs automated performances (I) 
After optimization of the manual protocol it was then transferred into an automated 
environment by introducing a Biomek® liquid handling robot during all the steps of the 
assay, with the exception of the cellular dispensing and the crystal violet addition steps 
that were performed with a Multidrop dispenser. A comparison was made between the 
manual and the automated assays in terms of the signal window, which is defined as the 
separation of the maximal signals (biofilm samples) and the minimal signals (TSB 
controls) (Figure 4). In addition, the assay performance in terms of statistical parameters 
was compared for the manual and the automated assay (Table 2 in Publication I). In the 
automated approach, the mean of the maximal signal decreased but the dispersion of the 
maximal signal points was also lower, resulting in similar Z’ values for both assays. The 
obtained Z’ values for both assays (> 0.4) can be regarded as an indicator of a well 
performing cell-based screening assay. Although the separation band was narrower in 
the automated assay due to the lower maximal signal and slightly higher minimal signal 
(Figure 4), a significant improvement in the repeatability measures was registered. This 
was due to that the plate-to-plate variability decreased from 3.50% to 0.64% and day-to-
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day variability was reduced from 35.2% to 8.90% when the automated performance was 
utilized. 
 
Figure 4. Signal window graph of crystal violet methods, filled symbols represent the manual assay 
and empty symbols the automated assay. Squares represent biofilm controls and triangles TSB 
controls. 3 x SDs of the controls are shown and the separation bands of the assays are the dashed 
lines. 
4.2.1.3 Validatory screening and antimicrobial susceptibility (I) 
The performance of the automated crystal violet assay was further tested by investigating 
the susceptibility to eight different antibiotics with previously reported effect on S. aureus 
bacteria (Table 2 in Publication I) and running a validatory screening campaign using a 
small in-house library of natural, commercially available, low molecular weight molecules 
(123 compounds, Figure 4 in Publication I).  
Planktonic bacteria were more susceptible to treatment than the biofilms, when using the 
most active antibiotic compounds. None of the antibiotics was able to kill more than 50% 
of the biofilms and thus, MIC50 for biofilms as well as both MIC50 and MIC90 for planktonic 
bacteria were established for the antimicrobials. The MIC50 ratios ranged from being 
equally effective to 1000 times more effective against planktonic bacteria than biofilms 
(Table 1 in Publication I). Rifampicin was found to be the most active against S. aureus 
biofilms followed by fusidic acid, penicillin G and oxacillin. For the planktonic 
counterparts, the most active agents were the same but in a slightly different order: 
rifampicin > penicillin G > oxacillin > fusidic acid. Polymyxin B, streptomycin and 
vancomycin had only minimal effect on biofilms and only a slightly higher effect on 
planktonic bacteria than on biofilms.  
The compounds found as positive hits in both prevention and destruction screening of 
the natural products collection, farnesol and lauryl gallate, have previously been reported 
to have antimicrobial and anti-biofilm activity against S. aureus bacteria (Kubo et al. 2002, 
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Jabra-Rizk et al. 2006, Unnanuntana et al. 2009). None of the other compounds in the 
screened library has been reported to be active against S. aureus biofilms, indicating that 
the assay was not giving rise to neither false positive nor false negative hits.  
4.2.1.4 Cryopreservation of biofilms for faster screening (I) 
To additionally improve the efficiency of the screening assay, a trial was performed using 
cryopreserved biofilms on plates. The typical biofilm assay testing takes four days when 
including all of the steps from preculturing the bacteria to staining the destruction 
experiment plate (see scheme in Figure 1 in Publication III). The use of cryopreserved 
biofilms would shorten the whole screening process from 4 to 2 days, as the biofilms 
could be grown in larger batches, stored and be used when needed without the need of 
re-culturing the bacteria and forming the biofilms.  
To validate this approach, the cryopreserved biofilms were compared with freshly 
prepared biofilms. Bacterial viability, as measured by CFU counts on TSA plates, was 
slightly decreased (although not statistically significantly) in 7 days-cryopreserved 
biofilms. In terms of assay performance, a slight increase was observed in the dispersion 
of the data points when using cryopreserved biofilms. This resulted in a decrease of Z’ 
(from 0.49 to 0.34) as well as S/B. Then again, the plate-to-plate variability was kept at 
about 3% when performing the assay with cryopreserved biofilms, but the day-to-day 
variability significantly decreased from 35% to 13%, when compared to the manual 
assay. In addition, the activity of eight model antibiotics was tested in cryopreserved and 
fresh biofilms and the results showed similar activities of the compounds on both biofilm 
types. 
4.2.2 The resazurin assay (II) 
4.2.2.1 Optimization of the performance 
Resazurin (7-hydroxy-3H-phenoxazin-3-one-10-oxide) is non-fluorescent and blue in its 
oxidized state and can be reduced by metabolically active cells to resofurin, which is 
highly fluorescent and pink (Guerin et al. 2001). The resofurin molecule can be further 
reduced to non-fluorescent and colorless hydroresofurin and thus, the staining time and 
the concentration used of the probe had to be optimized to find stable conditions for 
measuring the fluorescence. During the optimization experiments, 4 different stain 
concentrations as well as 6 different incubation times with the probe were tested. We 
found that 20 min incubation time using 20 µM resazurin was the shortest possible 
incubation time and lowest possible resazurin concentration providing statistically good 
performance results (Z’=0.66, S/N=9.41, S/B=10.56). Incubation time periods between 30 
and 120 min correspondingly provided statistically satisfactory signals, but they 
implicated longer duration assays with no significant benefits from the screening point of 
view. When the incubation was extended to 240 minutes, a reduction in the detectable 
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fluorescence signal was observed, which decreased the assay quality (from Z’>0.6 to 
Z’<0.4). This behavior was likely due to the accumulation of the colorless, non-fluorescent 
hydroresofurin.  
4.2.2.2 Planktonic calibration curve and detection limits 
The resazurin assay can also be directly applied to planktonic bacteria and it had 
previously been suggested that planktonic calibration curves could be used to estimate 
the number of bacteria in the stained biofilms (Toté et al. 2008). To be able to conduct a 
better interpretation of resazurin fluorescent signals and to establish the detection limit 
of the assay, the relation between planktonic and biofilms bacterial concentration was 
studied in closer detail (Figure 5). In both cases, a sigmoidal behavior of the fluorescent 
signal with increasing bacterial concentrations (as measured by actual CFU/ml in 
planktonic or biofilms) was registered. However, a preliminary comparative analysis of 
the curves reveals that similar resazurin fluorescent signals cannot be related to 
equivalent bacterial concentration in suspensions and in biofilms. The actual bacterial 
concentration associated with a certain fluorescent signal, is higher for cells in biofilms 
compared to in planktonic suspensions, i.e. at 100 RFU the actual bacterial concentration 
(in CFU/ml) was 59% higher for planktonic bacteria than for biofilm bacteria. A similar 
bacterial concentration generates a higher fluorescent signal when cells are in 
suspension, compared to biofilms at the similar cell concentration, i.e. at 1x108 CFU/ml 
the RFU for planktonic bacteria was 32% higher than for biofilm bacteria. A plausible 
explanation for this result is that it is indeed more difficult for the probe to be evenly 
distributed among the more densely packed biofilms cells than among suspended single 
bacterial cells. The metabolic activity among the cells in a biofilm varies and metabolically 
inactive cells can be present in the cellular core of the biofilm, causing a reduction of the 
fluorescent signal.  
The observation was made that the detection limit of the probe is high; concentrations 
higher than 5 x 107 CFU/ml are required of S. aureus bacteria in the well, to reach 
significant resazurin fluorescent signals for biofilm cells. However, such as in the crystal 
violet assay, the concentration required corresponds well to reported bacterial densities 
(107 CFU/cm2) in micro plate wells (Pitts et al. 2003). A linear increase-phase of the 
fluorescent signal was registered within a concentration range of 6 x 106 - 3 x 108 
CFU/ml. Under the optimal conditions identified in our assay, the fluorescent signal in the 
maximal signal wells (bacteria controls) is found at the end of this linear phase.  
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Figure 5. Relation between bacterial concentration (in CFU/ml) and relative absorbance units 
versus biofilms stained with resazurin. 
4.2.2.3 Assay performance 
The maximal (only biofilms) and minimal (only TSB) fluorescent control signals of this 
screening assay were normally distributed and clearly separated. Moreover, the average 
Z’-factor value calculated for the assay (0.66) as well as S/N (9.41), S/B (10.56) and CV 
(14.06%) indicated that the assay performs well, especially when taking into account that 
it is a cell-based method. The well-to-well, plate-to-plate and day-to-day variabilities 
were in all cases lower than 13%, which also support the assay repeatability as high.  
The resazurin assay consists of one very simple addition step. Performing the assay in 
manual conditions does not demand high labor efforts. Using an automated protocol 
would actually have increased the labor and prolonged the assay procedure. The 
procedure comprised about 30 seconds to manually add 200 µl per well in a 96-well 
plate, while in comparison, using the liquid handling robot it acquired more than 2 
minutes (using an 8-tip head multipipette, without changing the tips between columns). 
Furthermore, the robot had to be loaded with tips and reagents, which prolonged the 
time needed for the assay procedure. Automating the assay would not have represented a 
key necessity in order to screen libraries of moderate sizes.  
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Figure 6. Signal window of the resazurin assay. 3 x SD are shown for both maximal (squares) and 
minimal (triangles) signals (the SD of the minimal signal is very low and symbols exceed the lines). 
The separation band is shown with a dashed line.  
4.2.2.4 Validatory screening and antimicrobial susceptibility 
To evaluate the performance of the resazurin assay in a real setting, a validatory 
screening campaign of a chemical library was performed (Figure 7). A set of 6 
conventional antibiotics with known effects on S. aureus biofilms were randomly 
distributed within the screened plates to evaluate the assay reliability. Same antibiotics 
that showed some effect (fusidic acid, oxacillin, penicillin G, rifampicin and vancomycin) 
on the biofilms in the crystal violet assay were used in addition to methicillin.  
The library used in the validatory screening for the crystal violet assay was extended with 
low-weight compound derivatives, spanning through different chemical classes such as 
benzanilides, chalcones, imidazoles, thiophenes and thienothiazepines. In this screening 
campaign, the effects on the 18 h old biofilms were measured and no hits were found, 
other than the active antibiotics (listed above) to have an effect. The two compounds 
found positive in the first screening campaign, lauryl gallate and farnesol, were not 
reconfirmed here and apparently do not have an effect on the viability of the biofilms at 
the 40 µM concentration used in the screening. Neither farnesol nor lauryl gallate have 
been reported to be able to eradicate mature biofilms at this low concentration (Gomes et 
al. 2009, Kubo et al. 2003).  
In addition, the suitability of the assay to perform screening with natural extracts was 
also tested. The bacterial extracts from the ARMI collection were screened for destruction 
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of mature biofilms. In the initial screening, three extracts showed anti-biofilm activity. 
The complex composition of the bacterial extracts could make them more prone to 
interfere with the resazurin signal and appear as false negatives in the screening. 
However, the extracts showed no effect on the reduction of the resazurin probe. This 
proved the usefulness of the assay, as it can be suitable for pure compounds as well as for 
extracts. 
 
Figure 7. Screening graphs of 815 pure compounds using resazurin staining in destruction of 
mature biofilms. The shadowed area indicates positive hits in the screening. The hit limit is 
calculated as mean of control – 3 x SD. 
4.2.3 The wheat germ agglutinin assay (III) 
4.2.3.1 Optimization and detection limit 
This protocol was originally proposed by Burton et al. (2007) and it was based on the 
specific binding of the wheat germ agglutinin-Alexa Fluor 488 fluorescent conjugate 
(WGA) to poly-N-acetylglucosamine (PNAG) residues present in the typical EPS of 
Staphylococcus spp. biofilms (Burton et al. 2007). The original protocol proved a 
statistically well performing assay: several conditions were tested and in the end minor 
modifications were undertaken. Different concentrations (ranging from 0.01 to 10 µg/ml) 
of the WGA-Alexa 488 probe were tested and the original 5 µg/ml resulted in the best 
statistical performance and therefore it was considered optimal for use. The transfer of 
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the dissolved sample onto a new plate before measuring the fluorescence did not improve 
the assay and was hence removed from the protocol.  
To prove that the WGA assay was able to detect biofilms at the concentrations achieved in 
micro plate assays, the detection limit was established and compared with the previously 
established methods of the crystal violet and resazurin assays (Figure 8). If responses 
from the same compounds using the same three assays differ in terms of the detection 
limits, then conditions for bacterial biofilm formation need to be optimized again as 
comparisons between them could be limited. In this study, it was seen that the WGA assay 
could detect biofilm concentrations above 2x107 CFU/ml, which coincide well with the 
other two methods (Figures 3 and 5). Untreated biofilms reach up to 109-1010 CFU/ml, so 
a 3-log reduction could be measured using all of the above mentioned methods. The EPS 
has been reported to consist of extracellular DNA (eDNA) and proteins in addition to the 
polysaccharides (Steinberger and Holden 2005). To consider the activity of other 
molecules in the EPS, the biofilms were treated with DNase I and proteinase K to evaluate 
the effect of eDNA and extracellular proteins, respectively. DNase I did not show any 
effect on the biofilm at all. The treatment with proteinase K killed 23.9 ± 9.1% of the 
biofilms after 6 h treatment and 13.7 ± 8.4% after 22 h treatment. This indicated that 
neither eDNA nor proteins were a major constituent of the matrix of S. aureus biofilms.  
 
Figure 8. Relation between bacterial concentration and relative absorbance units versus biofilms 
stained with WGA. 
4.2.3.2 Performance and suitability 
The performance of the WGA assay made it amenable for screening purposes. The 
average Z’-values from carried out assays (both prevention and destruction) exceeded 
0.4. The maximal signal (biofilm controls) varied between 3 and 12 RFUs, but within the 
same experiment, the SD of the signal was kept low and the statistical parameters were 
good. Figure 9 shows the controls from six separate experiment plates, with the average 
of the statistical parameters as Z’=0.44±0.07, S/N=5.7±0.80, S/B=17.8±9.9.  
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Due to the wheat germ agglutinin assay being very laborious, requiring at least 3 h for the 
whole assay and using a relatively expensive probe, this assay was regarded to not be 
suitable for the primary screening stage. It is, however, important to take into account the 
effect of possible active compounds on the EPS as biofilm infections tend to re-emerge if 
matrix is left after treatment (Toté et al. 2008). This assay is therefore to be used in 
follow up studies of active screening hits. 
 
Figure 9. Control samples from six experimental plates, with individual Z’-factor values included. 
Filled symbols represent maximal signals (biofilm controls) and empty symbols represent minimal 
signals (TSB controls). 
4.3 Capillary electrochromatography –an additional biofilm method (IV) 
4.3.1 Optimization of the assay 
So far CEC has only been used for separation and analysis of planktonic bacteria (Desai 
and Armstrong 2003, Kłodzińska et al. 2009). As a novel approach, biofilms were 
immobilized in the capillary and the effect of various compounds on the biofilms could be 
studied. For the formation of biofilms in fused-silica capillaries, the first step involved the 
binding of the bacteria cells to the silica surface, which in the conditions used was 
negatively charged. This was conducted by growing biofilms on silica disks in Petri 
dishes, staining using the crystal violet assay and applying the statistically well 
performing conditions to the actual CEC apparatus. No biofilms could be formed on 
uncoated silica surface, due to the highly negative charge that is not present in 
polystyrene surfaces where the S. aureus bacteria adhere without problems (Gross et al. 
2001). Therefore, there was a need for a positively charged coating agent to increase the 
S. aureus binding to the inner surface of the capillary. Poly-L-lysine provided the surface 
with positively-charged amino groups forming an excellent base for the bacteria to 
adhere onto. The best biofilm attachment was achieved by coating the silica with 0.01% 
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of poly-L-lysine (Figure 2 in Publication IV). This concentration also provided the most 
stable surface in the capillary and was hence chosen for coating the inner surface of the 
capillary. The same results were also proven by imaging the biofilms formed on the 
coated silica and the capillary using AFM, and both the coated silica and the capillary 
showed bacterial aggregations of more than 300-500 nm, which confirmed the presence 
of biofilms (Figure 3 in Publication IV). The size of the biofilms matched previously 
reported AFM-studies (Tollersrud et al. 2001, Jonas et al. 2007). 
The stability was evaluated by measuring the mobility of the EOF during six successive 
runs. In order to evaluate the stability of the formed biofilm in the capillary, the mobility 
of the EOF was measured after first preconditioning the capillary and coating it with S. 
aureus biofilm corresponding to 17-20 h of biofilm formation in the capillary. The EOF 
mobility did not vary remarkably among the different coating times (Table 2 in 
Publication IV). The relative standard deviation values were, however, the lowest at 18 h 
and this incubation time was also used in the micro well plate approach and was chosen 
for use in optimal biofilm coating of the capillary in the future. To ensure the stability of 
the biofilm over time in the capillary, the EOF mobility was measured with 12 successive 
runs per day on 2 consecutive days. The results showed that the biofilm coating of the 
capillary was kept perfectly stable for at least the two-day period.  
4.3.2 Antimicrobial susceptibility 
The susceptibility of five of the same antibiotic compounds as in the crystal violet section 
was estimated in uncoated and biofilm coated electrochromatography capillaries using 
retention factors and reduced mobilities. The retention of the antibiotics by the biofilms 
was seen to decrease in the following order: penicillin > fusidic acid > oxacillin > 
vancomycin > rifampicin. The order of the interactions between biofilm and antibiotics 
followed the order for retention factor calculations; penicillin had the strongest 
interaction, followed by fusidic acid and oxacillin. Both vancomycin and rifampicin 
seemed to have very little interaction and were almost without effect on the biofilms. The 
rifampicin result was the only one that was contradictory to what was found in the micro 
well plate assay. The order of the antibiotics according to the biofilm MIC values in micro 
plates (stained by crystal violet, Publication I) was rifampicin (0.031 µg/ml) > fusidic acid 
(0.063 µg/ml) > penicillin (0.13 µg/ml) > oxacillin (0.25 µg/ml) > vancomycin (1 µg/ml). 
4.4 Applying the screening platform 
4.4.1 Combination of assays in a validatory study: a third method added (III) 
4.4.1.1 Resazurin and crystal violet assays performed in sequence 
First the performance of the screening platform was improved by combining resazurin 
and crystal violet measurements to one plate in a sequential workflow. Resazurin was 
proven not to have any effect on the following crystal violet staining, for crystal violet 
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staining of biofilms in the same plate as resazurin RAU was 1.52 ± 0.25 compared to 
crystal violet stained biofilms in a separate plate gave RAU = 1.57 ± 0.29. No statistically 
significant change was detected (p=0.4149). A scheme of the whole experimental 
sequence is visualized in Figure 1 in Publication III. 
4.4.1.2 Susceptibility studies using known antimicrobial compounds 
The combination of the three assays in a susceptibility study of three model compounds 
was performed using ciprofloxacin and penicillin G as active compounds and rosmarinic 
acid as a negative control (Figure 10). Ciprofloxacin and penicillin G significantly reduced 
the viability, the biomass and the EPS layer in the prevention approach. Rosmarinic acid 
is a weak antimicrobial agent and only slightly reduced the viability, but had no effect on 
the total biomass and the EPS. When the compounds were added to mature biofilms, the 
rosmarinic acid did not show any effect. Both ciprofloxacin and penicillin G were able to 
reduce the biomass and the viability significantly but in the case of ciprofloxacin 
unchanged WGA signal was detected compared to the control. Biofilms treated with 
penicillin showed a drastically elevated WGA signal that was more than 200% of the 
control. 
In addition, fluorescence microscopy was used to confirm the results obtained with the 
WGA and resazurin assays (Figure 4 in Publication III). For that purpose, images were 
taken in samples stained with WGA and the LIVE/DEAD probe that provides a functional 
response distinguishing living and dead cells, in a way comparable to the resazurin signal. 
Penicillin G (400 µM) gave a nearly 50%-reduction of the viable cells compared to 
untreated cells (G/R ratio) visualized by the LIVE/DEAD stained sample. In contrast, the 
surviving cells clearly produced more EPS and increased the green fluorescence in the 
treated sample compared to the control sample (Figure 4 in Publication III).  
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Figure 10. The effects of three model compounds in (A) prevention of and (B) destruction of S. 
aureus biofilms utilizing the combination of the three assays of the platform (resazurin - black bars, 
crystal violet - grey bars and WGA - white bars), are shown here. One-way ANOVA comparisons and 
Tukey post tests were applied to the original data points but for better clarification, only the results 
of the comparisons between the untreated biofilms and the highest concentration of the two 
compounds are presented here. *** indicates a high statistical significance in the difference from 
the control, p<0.001. 
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By investigating the effect of the treatments on other biofilm-forming strains, this 
phenomenon could be excluded to be a strain-specific artifact. For S. aureus Newman 
strain and E. coli (XL1 Blue) the same increase of the WGA signal was measured for 
penicillin G treated biofilms. The EPS of S. epidermidis RP62A was not affected by any of 
the antibiotics. S. epidermidis ATCC 12228, on the contrary, was not showing reliable 
WGA-signals (even negative Z’-values were received). As a result it seems like that the 
WGA-assay is dependent on PNAG production, as this strain is lacking the icaADBC 
operon and is not producing any PNAG. 
4.4.2 A pilot study (V) 
4.4.2.1 The screening campaign for anti-biofilm activity 
A cinchona alkaloid library containing the natural cinchona alkaloids cinchonidine and 
cinchonine as well as 22 of their analogues and derivatives was initially screened for 
investigating the effect on planktonic bacteria (Figure 11A). The entire library was also 
screened for activity in preventing biofilm formation (Figure 11B) and destruction of 
mature biofilms (Figure 11C) using the initial screening approach with staining the 
biofilms sequentially with resazurin and crystal violet. The same active compound was 
also able to prevent biofilm formation, but had no effect on mature biofilms at the 
concentration used in the screening. 
No antimicrobial effect was found for the original compounds cinchonidine or cinchonine, 
whereas one derivative inhibited the growth completely, 11-triphenylsilyl-10,11-
dihydrocinchonidine (11-TPSCD). The most distinctive feature of this molecule is the 
triphenylsilyl group in position 11, which is absent in all the other molecules of the 
library, except for compound 9-TMSO-11-TPSCD (11-triphenylsilyl-9-O-trimethylsilyl-
10,11-dihydrocinchonidine (Figure 12). However, 11-TPSCD has a free OH group in 
position 9 that is blocked in 9-TMSO-11-TPSCD by a trimethylsilyl group. Thus, these two 
structural features seem to be crucial for high activity of 11-TPSCD, in contrast to the 
other cinchonidine derivatives from the library.  
 
Figure 11. Screening graphs for planktonic, prevention, and destruction assay results. The active 
compound, 11-TPSCD is marked in red in all the graphs. 
0
50
100
150
0 5 10152025
%
 o
f 
b
ac
te
ri
a 
co
n
tr
o
l
screened compounds
0
50
100
150
0 50 100%
 b
io
fi
lm
 c
o
n
t.
 
(r
es
az
u
ri
n
)
% biofilm cont.(crystal violet)
0
50
100
150
0 50 100
%
 b
io
fi
lm
 c
o
n
t.
 
(r
es
az
u
ri
n
)
% biofilm cont.(crystal violet)
A. C. B. 
Results 
 
55 
 
 
Figure 12. The structures of the active hit compound 11-TPSCD (A) and the structurally related 9-
TMSO-11-TPSCD (B). The cinchonidine part of the structures is indicated in black and the 
substitution parts are marked in red. 
4.4.2.2 Follow up studies 
Potencies (IC50s) were determined for the active cinchonidine derivative against 
planktonic bacteria as well as biofilms in prevention and destruction. For planktonic 
bacteria and the prevention of biofilms, the IC50s were low, 6.11 µM (planktonic), 6.56 µM 
and 2.21 µM (prevention of biofilms resazurin and crystal violet, respectively). For 
destruction of mature biofilms, the potency values as measured by IC50 values were 212 
µM and 225 µM for resazurin and crystal violet staining, respectively.  
Figure 13. Fluorescence microscopy images of untreated biofilms (A), biofilm treated with 11-
TPSCD (B) and TSB control (C). The imaging was conducted with the fluorescent LIVE/DEAD® 
BacLight™ commercial kit. Alive cells are stained green with SYTO 9 and dead or ruptured cells are 
stained red with propidium iodide. The ratios of green-to-red fluorescence (G/R ratio) quantified 
from parallel samples are shown in D. The scale bars equal 100 µm. 
B. Biofilm + 11-TPSCD (215 µM) 
  
 
A. Untreated biofilm 
C. TSB control 
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Imaging studies were carried out in parallel to confirm the anti-biofilm activity of 11-
TPSCD by fluorescence microscopy (Figure 13). An untreated biofilm control sample, a 
TSB control sample and a biofilm sample treated with 215 µM 11-TPSCD were imaged. 
The ratio between the green and the red fluorescence in the samples were calculated.  
The reduction of the biofilm amount by treatment with the active compound was 
quantified using log reduction. In the prevention assay, the log R values (the difference in 
logCFU/ml in treated and untreated samples) were 2.1 at 10 µM for biofilms and 3.9 for 
the planktonic phase. Log R values in the destruction assay were at 200 µM, 2.7 for 
biofilm bacteria and 4.9 for the planktonic bacteria. 
The effect of the active compound on the EPS layer was also determined by the WGA 
assay. In prevention, a slight decrease in the signal could be observed at concentrations 
ranging from 5 to 10 µM (14-31% of inhibition), higher concentrations (20-100 µM), 
however, increased the WGA-signal to 118-165% of the control. In destruction, no effect 
compared to untreated biofilms could be observed. This indicates that the compound is 
not fully able to remove the biofilms. However, in combination with a dispersing agent, 
the compound could be effective, by killing planktonic bacteria and preventing biofilm 
formation. 
4.4.2.3 Screened compound locations in chemical space 
To explore the chemical space occupied by the active compound 11-TPSCD, the 
antibiotics and the non-active compounds from the cinchona alkaloid library, as well as 
all the other compounds used in the validatory screening campaigns, a comparative study 
was performed using the ChemGPS-NP tool. ChemGPS is a Principal Component Analysis 
(PCA)-based chemical space navigation tool applicable to natural products (Larsson et al. 
2007, Rosén et al. 2009).  
In Figure 14, it is demonstrated that the cinchona alkaloid derivatives populate a fairly 
similar chemical space when compared to the other screened libraries. The cinchona 
alkaloids were characterized by low molecular sizes (given by PC1), high aromaticity 
(given by PC2) and restricted flexibility (given by PC4, not shown here). The compounds 
were quite evenly distributed between hydrophilic or hydrophobic compounds (PC3). 
The antibiotics were the ones most widely spread over the chemical space presented 
here. The largest antibiotics (amphotericin B, polymyxin B, rifampicin and vancomycin) 
represent both active (green dots) and non-active antibiotics (blue dots) and were the 
most distant from the rest of the compounds. The rest of the antibiotics are low molecular 
weight compounds and were distributed among the rest of the compounds. The non-
active antibiotics were the least aromatic. The active hit compound, 11-TPSCD (red dot), 
was found to be located in a slightly more lipophilic region than the rest of the 
compounds together with its non active analogue, 9-TMSO-11-TPSCD. It appears like 
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there is no specific space for antimicrobial compounds; they vary in all three dimensions. 
The hit compound 11-TPSCD supports the fact that also compounds with anti-biofilm 
activity can be found outside the drug- and lead-like space defined by Lipinski (2001) and 
Teague (1999).  
Figure 14. Three-dimensional representation of the chemical space occupied by all of the 
compounds (829 compounds) screened for anti-biofilm activity using the PCA-based navigation 
tool ChemGPS-NP, as described in publication V. The cinchona alkaloid library is represented by the 
purple dots, the hit compound 11-TPSCD by a red dot, the natural product library is represented by 
black dots and the chemical library by grey dots. The active antibiotics are marked in green and the 
non-active antibiotics in blue. 
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5 Discussion 
5.1 Antimicrobial and anti-biofilm research and screening against 
biofilms 
Antimicrobial resistance is an evolving problem and there is a lack of effective agents. In 
spite of this, antimicrobial drug discovery is not a favored area for pharmaceutical 
companies today (Moellering 2011). The reasons are understandable as the promised 
techniques introduced about 20 years ago by genome sequencing of micro-organisms and 
combinatorial chemistry for gene target based high throughput screening campaigns 
have not provided the much sought after results (Payne et al. 2007). However, there are 
multifactorial reasons explaining the failure of screening campaigns. Regarding only the 
targets and the libraries used; the need of validation of targets in every species used, in 
vivo validation, rapid resistance development, and the libraries used for screening are 
often containing very few compounds with the physical-chemical properties suitable for 
antimicrobials are reasons for failure (Brötz-Oesterhelt and Sass 2010). The fact that if an 
effective antibiotic is found, it most probably would not be a high-profit product for the 
company investing in developing it as it has to be used with caution to avoid the 
occurrence of resistance (ECDC/EMEA 2009, Fox 2006). One advantage antimicrobial 
drug compounds have over many other drug compounds is the high predictive value of 
the animal models that are used for in vivo studies. This is due to the fact that most of the 
pathogens causing problematic infections in humans also infect animals (Payne et al. 
2007). In many cases, the same strains have been detected in humans and animals, and 
this is also forging a new thinking in veterinary use of antimicrobials to prevent the 
evolving of more resistant strains due to overuse of antimicrobials to treat animal 
infections (ECDC/EMEA 2009). Nevertheless, economically feasible or not, the problem 
remains and progress as, biofilms are currently regarded as the cause of a majority of all 
severe infections (Kiedrowski and Horswill 2011). Until other effective antibiotics are 
found, currently existing moderate compounds will be needed to keep the pathogen 
problems under control and in order to do that, effective assays for screening will be 
required (Fox 2006). 
Whole-cell screening as opposed to target-based screening has re-emerged into the 
antibacterial drug discovery (Gwynn et al. 2010). This is due to the fact that targets have 
been problematic. Single specific gene targets have been prone to resistance development 
and multiple targets would be beneficial instead. Complex mechanisms rather than 
simple enzyme inhibition functions have given better results as well (Brötz-Oesterhelt 
and Sass 2010). The drawback of whole-cell primary screening is the unspecific mode of 
action of potential hits (Brötz-Oesterhelt and Sass 2010). Many of the existing 
antimicrobial agents are naturally produced or semisynthetic derivatives of natural 
products. Erythromycin, vancomycin and daptomycin from actinomycetes or fungi are 
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examples of compounds that have been found by whole-cell screening methods, even 
without knowing the exact mechanism (Baltz 2007). However, quorum sensing (QS) 
targeting screening has, for instance, been suggested to be an effective anti-biofilm 
screening approach (Landini et al. 2010). For gram-negative P. aeruginosa biofilms there 
are several well-established QS-targets, such as the las and the rhl systems (Sintim et al. 
2010). In S. aureus biofilms, there is the autoinducing peptide (AIP) based agr and the 
luxS systems that have been shown to play a role in virulence of S. aureus biofilms (Kuehl 
et al. 2009). It has been shown that the susceptibility of gram-positive and gram-negative 
biofilms to antibiotics might be enhanced by suppression of the QS-system, even though 
the QS-suppression itself was not enough (Brackman et al. 2011). Therefore, the impact 
of quorum sensing for biofilm formation and virulence does not seem to be a straight 
forward approach. The fact that, with the exception of a few QS-suppressor-mimicking 
molecules, the targets of the anti-biofilm agents found are not known (Sintim et al. 2010). 
The applicability of the lead molecules found by target-based screening has been limited 
by the lack of activity when they are tested in cell-based assays (Baltz 2007). This has 
prompted to favor the use of whole-cell based assays during the initial chemical 
screening to identify lead molecules, followed by target specific assays in a secondary 
screening phase, to establish the mode of action of tentative leads (Payne et al. 2007). For 
this reason, in this study, it was chosen to develop a platform of whole-cell based 
screening assays against S. aureus biofilms. 
S. aureus is a clinically relevant strain causing severe infections and can currently be 
nosocomial and community-acquired. The infections are difficult to treat, probably due to 
biofilm formation (Kiedrowski and Horswill 2011). Biofilms show multidrug resistance 
that can even be increased if the initial treatment has been too mild to eradicate the 
biofilm completely (Hall-Stoodley and Stoodley 2009). Additionally, it is difficult to 
diagnose a severe infection as to have been caused by biofilms and thereby be able to 
administer the correct treatment (Hall-Stoodley et al. 2004). There are diagnostic criteria 
for biofilm infections including demands of being surface attached, showing microbial 
aggregates in localized infections with resistance to antibiotics with or without culturing 
the bacteria, as well as ineffective host clearance, but they are hard to determine in a 
timely fashion (Parsek and Singh 2003, Hall-Stoodley and Stoodley 2009). Poor 
diagnostics lead to requirements of rapid treatments with effective broad spectrum drugs 
(Brötz-Oesterhelt and Sass 2010). However, there is no diagnostic method or specific 
biofilm marker for Staphylococcus spp. biofilm infections and they remain challenging to 
treat (Bordi and de Bentzmann 2011). The S. aureus ATCC 25923 strain has been a widely 
used reference strain for antimicrobial research (Kronvall 1982, Ozturk et al. 2008), i.e., 
as well as for biofilm research (Zmantar et al. 2010, Singh et al. 2010), i.e. 
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5.2 The chosen assays in comparison with other biofilm assays  
Crystal violet is a widely used method for studying bacteria in biofilms (Djordjevic et al. 
2002, Li et al. 2003, Peeters et al. 2008). The method was first used in tubes and was later 
optimized for micro well plates (Christensen et al. 1985, Stepanovic et al. 2000). The 
assay is based on the use of available, inexpensive reagents, with a simple absorbance 
endpoint reading. Staining biofilms with the crystal violet assay requires several washing 
steps and when dealing with screening campaigns on several plates this signifies a great 
number of dispensing and aspiration steps performed by hand. This issue was solved in 
publication I by using automation with a liquid handling robot that easily manages 
dispensing and aspiration.  
The most serious drawback of the method is the fact that it only measures total biomass 
and is, therefore, not applicable to viability measurements (Li et al. 2003, Pitts et al. 
2003). This drawback is targeted by the addition of the viability measuring resazurin 
assay to the primary screening platform (Publication II).  
Resazurin is a very fast (single-addition) and non-laborious method based on a single 
addition step of a non-fluorescent probe, which is reduced by metabolic activity to a 
fluorescent compound (Pettit et al. 2005). However, this method requires optimization 
for every separate strain it is used with. An example of optimization of the performance 
of this assay was presented in publication II. A wide variety of experimental protocols 
had been used according to the literature and both the concentration of the probe and the 
incubation time for staining the S. aureus biofilms in these experiments had to be 
validated. It was demonstrated from that study that 20 µM final concentration of the 
probe and 20 min incubation time were the fastest optimal conditions found for the 
screening purpose. The importance of optimization when taking a new strain into use 
was seen in publication III when we used additional biofilm strains for the combination 
of the assays. For the two Staphylococcus epidermidis strains and S. aureus strain Newman 
used, the same conditions as for the original strain could be conducted. In contrast, 
staining E. coli biofilms with resazurin, required a longer incubation time with the probe 
to give an appropriate signal. Peeters et al. (2008) optimized the resazurin assay for 
several different strains and came to the conclusion that 1 h was an appropriate 
incubation time for all the strains (yeast, gram-positive and gram-negative bacteria) 
except for S. aureus that required shorter incubation (30 minutes). Toté et al. (2008) 
similarly used 30 minutes for S. aureus biofilms. Pettit et al. (2005, 2009) used 1 h 
incubation for S. epidermidis. 
Another important factor that was found in this study during the resazurin optimization 
was the difference in responses when the resazurin assay is applied to the staining of 
planktonic and biofilm bacteria. Previously it had been suggested that bacteria 
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concentration of biofilms could easily be estimated by using a titration curve done with 
planktonic bacteria (Toté et al. 2008). This, however, is clearly not the case. It was seen 
that higher concentrations of biofilm bacteria compared to planktonic bacteria were 
required to achieve similar resazurin signal (Figure 3).  
Other viability probes such as XTT, FDA and SYTO 9 have also been successfully 
optimized for biofilm staining. In a comparison study with different biofilm forming 
bacteria and fungi, resazurin and FDA were found to be the most favorable assays 
(Peeters et al. 2008). Both XTT and SYTO 9 are performing-wise usable but they are 
expensive and XTT is also much more laborious to use than the resazurin and FDA assays 
(Peeters et al. 2008). The most cost-effective reagent is resazurin (according to 
concentrations used and prices provided by Sigma Aldrich) and is clearly not toxic to the 
biofilms.  
There is no single method that can measure the effect of a compound on viability, 
biomass and the EPS layer at the same time. Therefore, there is a need for combining 
assays to be able to detect an effect on all three features already at a primary screening 
stage. Because the resazurin compound is not toxic to the cells, crystal violet could be 
performed on the same sample after concluding the resazurin assay without interfering 
with the outcome (O'Brien et al. 2000). In the present study, this was a remarkable 
improvement of the workflow and it lowered costs and time needed for the experiments. 
The assay platform was also shown to be reliable from the validatory screening 
campaigns performed for each assay separately, as only compounds with reported 
antimicrobial and/or anti-biofilm activity were detected. 
Biofilms are built not only from the viable bacteria but of the self-produced extracellular 
polysaccharide matrix surrounding them as well. To measure the production of this 
matrix, a third assay was used based on the fluorescence staining with WGA. A 
comparison of the three biofilm quantification assays showed that they have similar 
detection limits (107 CFU/ml), which correspond well with concentrations generally 
measured for biofilms in micro well plates (Pitts et al. 2003). This also enables the assays 
to be used together without need of thorough optimizations of biofilm formation 
conditions.  
The combination of the three assays optimized in this thesis, allowed an overall picture of 
the anti-biofilm effects of compounds in terms of biomass, viability and EPS production. It 
had previously been noticed that certain antibiotics could apparently have positive 
effects on biofilms by causing a significant decrease of biomass and viability, but still 
leave the EPS unaffected (Toté et al. 2009). Based on these results, Toté et al. proposed a 
classification of antibiotics in connection to their effects on biofilm bacteria and matrix. 
We proposed in publication III that a sixth category of compounds could be added to the 
list (Table 1). These types of compounds, exemplified in our case with penicillin G, have a 
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significant effect on decreasing the viability and the total biomass, but the EPS are 
simultaneously increased upon compound exposure. The other model antibiotic used, 
ciprofloxacin, was able to decrease the viability and the biomass, but had no effect on the 
EPS layer of S. aureus biofilms (Publication III). Ciprofloxacin could as a consequence be 
added into the fourth category proposed by Toté et al. (2009) along with kanamycin that 
displays similar effects against P. aeruginosa biofilms (Toté et al. 2009). The same effect 
on the EPS levels caused by penicillin G was also proven to occur in another S. aureus 
(Newman strain) and E. coli (XL1 Blue) biofilms, confirming that the registered results 
were not exclusive to the model strain used here. Leaving the EPS can be the cause of a 
re-emerging biofilm infection, as there can be latent cells left protected in the slime or the 
pre-existing slime layer can enhance attachment of bacteria and promote biofilm 
formation (Toté et al. 2008). This would ultimately affect the long-term 
chemotherapeutical effects of antibiotics against biofilms.  
Table 3. Antibiotics divided into categories based on their effect on the biofilm bacteria and the 
matrix. Modified from Toté et al. (2009).  
Category Effect on 
bacteria
a 
Effect on 
matrix
a 
Example antibiotic 
(target biofilm
c
) 
Reference 
1 none none ampicillin (SA) (Toté et al. 2009) 
2 none ‒ cefalotin (SA) (Toté et al. 2009) 
3 ‒ none polymyxin (SA) (Toté et al. 2009) 
4 ‒ ‒ kanamycin (PA) 
ciprofloxacin (SA) 
(Toté et al. 2009) 
Publication III 
5
b
 ‒ (+) ‒ doxycycline (PA) (Toté et al. 2009) 
6 ‒ + penicillin G (SA, EC) Publication III 
a
 none; no effect, ‒; decreased, +; increased 
b
 includes compounds having an increased effect at sub-MIC levels. 
c
 biofilm strains, SA – S. aureus, PA – P. aeruginosa, EC – E. coli. 
Toté and colleagues (2009) used dimethylmethylene blue (DMMB) that has been used for 
quantification of sulphated polysaccharides because it binds glycosaminoglycans (GAG) 
in biological samples (Barbosa et al. 2003). The similarity of GAG to the polysaccharide 
intercellular adhesin (PIA) that is a major component in Staphylococcus spp. biofilms, 
makes the DMMB probe suitable for quantification of the biofilm matrix (Toté et al. 
2008). The method used in publication III similarly targets the PIA of the Staphylococcus 
spp. biofilm matrix but is based on the specific binding of wheat germ agglutinin to poly-
N-acetylglucosamine PNAG residues in the biofilm matrix (Burton et al. 2007). PNAG is 
also involved in biofilm formation by both gram-positive and negative strains. The 
icaADBC-operon has been shown to be required in the genome for PNAG production in 
Staphylococcus spp. (Gerke et al. 1998), and the pgaABCD-operon in E. coli (Cerca and 
Jefferson 2008). The importance of PNAG was seen with the S. epidermidis ATCC 12228 
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strain, which lacks the ica-locus (Zhang et al. 2003) and the WGA-assay was not 
applicable to that strain (Publication III). There was no replicability and the signal 
variation was too high, even negative Z'-values were received. The WGA assay for 
quantification of the biofilm matrix was originally described as an enzyme-linked lectin-
sorbent assay (ELLA) by Thomas et al. (1997) and was further optimized by Burton et al. 
(2007) using the wheat germ agglutinin Alexa Fluor 488-conjugate. The Alexa Fluor 488 
conjugation enables fluorometric readout, which simplifies the assay (Burton et al. 2007).  
The CEC-method (Publication IV) allows for a completely novel way of studying biofilms 
and the effect of complex mixtures on biofilms. The growth conditions are simple to 
change because the flush of bacteria is constant. It can be compared to methods using 
constant flow for the growing environments, such as the Robbins device where biofilms 
are formed on a surface in a flow of nutrients and fresh bacteria (Linton et al. 1999). The 
CEC-method proved in the present study to be reliable for growing biofilms when 
compared to the crystal violet micro plate based assay. The effect of the antibiotics was 
similar with the exception of rifampicin. In the micro plate assays (also resazurin) it was 
shown to be the most active agent against biofilms. In the CEC, however, rifampicin did 
not show any interaction with the biofilm in the capillary in contrast to the other active 
agents and was considered to be the least active compound against biofilms (Figures 4 
and 5 in Publication IV). Previous research has shown that antibiotics might bring about 
varying results when the assay format is changed (Tammela et al. 2004). In another study 
of the impact of different anti-biofilm agents on the viscoelastic properties of the biofilm 
structure, rifampicin was shown to alter the mechanical properties of the biofilm (Jones 
et al. 2011). The rifampicin might have caused physical changes in the biofilms 
subsequently causing the discrepant signal in the CEC. 
5.3 Screening for new chemical structures and bacterial extracts 
In the screening of the cinchona alkaloid library, the primary screening platform of 
resazurin and crystal violet staining was used (Publication V). Only one compound (11-
TPSCD) was able to reduce the viability and the biomass in screening for prevention of 
biofilm formation. Using the crystal violet assay, two compounds (9-TMSO-11-TPSCD and 
11-TPSCD) were found to be beneath the hit limit. 9-TMSO-11-TPSCD, however, had no 
effect on the viability of the biofilms and was not considered for further studies. The 
active 11-TPSCD and the non-active 9-TMSO-11-TPSCD compounds were found to be 
occupying a slightly different area in the chemical space than the rest of the screened 
compounds. However, only one of them was active leading to the conclusion that the 
physico-chemical properties cannot be the only explanation for the activity. The active as 
well as and the non-active antibiotics were widely spread over the chemical space, 
implying that biofilms are complicated to eradicate and that active anti-biofilm 
compounds can be found in different locations in chemical space. This approach of using 
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small targeted libraries for a single aim is not only the proceeding of small academic 
laboratories, but of large pharmaceutical companies, like GSK, where they have tried this 
approach when large multi-target screening campaigns had failed (Payne et al. 2007). The 
active compound does not fall within all the Lipinski's rule of five (slightly larger and 
more lipophilic) but it has been stated that many natural products as well as 
antimicrobials are exceptions to the rule (Coates and Hu 2007, Newman and Cragg 2007). 
Maybe there would be requirements for new rules for the screening of antimicrobials or 
when using natural products. As proposed by i.e. Payne at al. (2007), the screening 
campaigns could be concentrated to fewer compounds (i.e. small natural products 
libraries). Interesting compounds from these small libraries could then be chemically 
modified, if needed. However, the amount of unexplored natural chemical space is so 
wide that the right structure for activity most probably does exist; the difficult part is the 
strategy to find it. Thus, the development of effective methods compatible for testing 
compounds, including natural products, against chosen targets is of great importance. 
One future direction is to use natural products for drug development; especially in field 
like antimicrobials where the usual compound demands are not the most suitable. The 
use of crude extracts is also an interesting strategy, especially combined with fast and 
effective methods for separation and identification of the pure substituents (Vuorela et al. 
2004).  
A library of bacterial extracts was also used for validatory screening of the resazurin 
method and two extracts were displaying clear anti-biofilm effects in both prevention and 
destruction of biofilms (unpublished results). Screening libraries of natural product 
extracts have been revisited since many large screening campaigns with pure compounds 
have failed (Payne et al. 2007). Earlier extract screening was the primary source for drug 
screening, but was then considered to be too laborious and abandoned for pure 
compound libraries in the era of synthetic chemistry (Grabley and Sattler 2003). 
Nevertheless, with modern technologies extracts can be efficiently microfractionated and 
identified (Vuorela et al. 2004). Especially in the field of antimicrobial agents, the natural 
product extracts have shown interesting results. Additionally, the physico-chemical 
properties of natural products seem to coincide quite well with antimicrobial and 
targeted libraries with natural product scaffolds (Payne et al. 2007, Brötz-Oesterhelt and 
Sass 2010). It is also possible that there is not one single active component, but rather a 
combination of several which provides the activity. Indeed, the first mixture of 
compounds was approved for drug use by the FDA in 2007 and in Europe in 2010 
(Mishra and Tiwari 2011). Bacteria clearly represent the largest biodiversity (Pace 1997, 
Pace 2009). The Arctic Microbes culture collection (ARMI) used in the screening 
comprises bacteria isolated from arctic environments and they most likely possess 
interesting components for survival in the harsh conditions they were isolated from 
(Männistö and Häggblom 2006). Micro-organisms from marine environments are also yet 
unexplored to a large extent and are of present interest for the drug discovery research 
(Leal et al. 2012). 
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6 Conclusions and future perspectives 
Biofilms are the cause of very severe infections and S. aureus, especially, has been a 
troublesome pathogen in nosocomial infections. The dauntingly rapid development of 
resistance among these pathogenic bacteria increases the necessity of novel effective 
antibiotics. The majority of all bacteria are able to form biofilms and it is currently 
believed that existing in biofilm format is actually the preferred bacterial lifestyle. 
However, the existing antibiotics as well as the methods for studying bacteria have been 
developed for planktonic bacteria, which basically make them unusable for biofilm 
studies.  
In the project at hand, the overall aim was to fill the void of biofilm assays suitable for 
screening. For this purpose, a statistically robust platform of three assays amenable for 
anti-biofilm screening was developed. Three very important features of biofilms, essential 
from a drug discovery perspective, were targeted using three separate assays carried out 
in sequence succeeding each other. We propose that the effects that the screened 
compounds have on biomass (Publication I) and viability (Publication II) can be studied 
at a primary screening stage using crystal violet and resazurin, respectively. Positive hits 
could then be followed up by investigating the effects on the EPS-layer (Publication III), 
in order for true hits, with positive effects on viability, biomass and matrix could be 
identified. The CEC-method is providing an additional way of studying interaction 
between compounds and biofilms in a continuous flow system (Publication IV). Smaller 
institutions, such as academic groups or small companies, could utilize this platform of 
methods for anti-biofilm screening. They are perhaps interested in screening a specific 
library or against a certain biofilm strain, but lack the interest or knowledge in 
developing the assays.  
Large pharmaceutical companies have failed in finding new antimicrobial drugs in their 
large screening campaigns using compounds that fulfill the drug-like properties 
established by Lipinski (2001). Consequently, natural products have been left out in some 
cases from large screening libraries due to not fulfilling the drug-like properties. Both 
antibiotics and natural products are mostly larger and more hydrophilic and it has been 
suggested that targeted libraries of natural products-like compounds could be successful 
in the search for new antimicrobials.  
A total of 820 small molecular, mostly naturally derived compounds, were screened 
during the validation steps of the current study’s assays. In the pilot study (Publication 
V), where the whole platform was utilized using a small library of cinchona alkaloids, one 
novel compound, 11-TPSCD - a derivative of cinchonidine - was found to have 
antimicrobial activity against planktonic bacteria. The compound was also able to prevent 
biofilm formation at a low micromolar concentration and eradicate mature biofilms at a 
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higher concentration. Still, no effects were found on removing the EPS layer using the 
WGA-assay.  
Nature is to a wide extent still unexplored, marine and extreme environments in 
particular. Thus, there are certainly natural products to find with interesting activities in 
antimicrobial and anti-biofilm research. The difficulties lie in finding them and 
economically motivate the research, while with the knowledge that if a potential 
compound is found and developed into a drug it has to be saved for seriously threatening 
situations, such as risks of pandemics. This, however, makes antimicrobial research an 
increasingly important field and to be able to find the active compounds new strategies 
are required, especially in the field of anti-biofilm compounds.  
This project could be continued by further screening additional libraries, including 
targeted natural products and extract libraries. Another interesting input would be to 
optimize the platform for other biofilm-forming strains. Gram-negative strains are the 
new threat for pandemic outbreaks, for example the multi-resistant EHEC-bacteria (WHO, 
2011). Also other dangerous pathogens that are known to form biofilms could be used as 
target in this screening platform. 
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Appendix 1 
Antibiotics with reported anti-biofilm activity against the most common biofilm producing strains. 
Trade names for compounds used clinically for severe infections in Finland. 
Antibiotic Year
a 
Target organism  Biofilm MIC Origin
b 
References
c
  
amoxicillin 
AMORION 
AMOXICILLIN 
AMOXIN 
+ clavulanic acid 
AMORION COMP 
AUGMENTIN 
1972 
 
 
 
1980 
Streptococcus 
pneumoniae 
 
 
E. coli 
8 mg/l 
 
 
 
5-6 mg/l 
NPD del Prado et al. 
2010 
 
 
 
Rodríguez-
Martínez et al. 
2007 
ampicillin 
A-PEN 
1961 S. aureus 
 
128 mg/l  NPD Olson et al. 2002 
amikacin 
BIKLIN 
1970
s 
S. aureus 
P. aeruginosa 
 
4-64 mg/l 
NPD Singh et al. 2009 
King et al. 2010 
azithromycin  
AZITHROMYCIN 
ZITHROMAX 
1988 P. aeruginosa  
S. aureus  
Candida albicans 
 
 
 
NPD Bala et al. 2011 
Wu et al. 2010 
Ku et al.2010 
aztreonam  
AZACTAM 
1984 P. aeruginosa  
 
 NPD Moskowitz et al. 
2004, Field et al. 
2005, Høiby 2011 
cefalexin 
KEFALEX  
KEFEXIN 
1967 S. aureus 
 
8 mg/l NPD Haddadin et al. 
2010 
ceftazidime  
CEFTAZIDIM 
GLAZIDIM 
1990 P. aeruginosa  
 
 NPD Riera et al. 2010 
 
ceftriaxone  
CEFONOVA 
CEFTRIAXON 
ROCHEPHALIN 
1982 S. epidermidis 600-2400 mg/l NPD Hajdu et al. 2009 
cefuroxime  
CEFUROXIM 
ZINACEF 
ZINNAT 
1987 E. coli 1.3 mg/l 
(prevention) 
NPD Koseoglu et al. 
2006 
ciprofloxacin  
CIPROFLOXACIN 
CIPROMED 
CIPROXIN 
SIPIRON 
1986 P. aeruginosa  
 
 Synthetic Brooun et al. 2000 
 
clarithromycin  
CLARITHROMYCIN 
KLACID 
ZECLAR 
1990 S. aureus  
P. aeruginosa 
4 mg/l 
200 mg/l 
NPD Aguinaga et al. 
2011 
Tré-Hardy et al. 
2009 
clindamycin 
CLINDAMYCIN 
CLINDOXYL 
DALACIN 
1970 S. aureus 
 
 NPD Huang et al. 2012 
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cloxacillin 
CLOXACILLIN 
STAFLOCIL 
1960 S. aureus 
 
512 mg/l NPD Olson et al. 2002 
daptomycin 
CUBICIN 
2003 S. aureus 
S. epidermidis 
 Natural Domínguez-
Herrera et al. 
2012, Leite et al. 
2011a 
doxycycline 
DOXIMED 
DOXIMYCIN  
DOXITIN  
1967 C. albicans 
Enterococcus faecalis 
256 mg/l NPD Miceli et al. 2009 
Saber and El-Hady 
2012 
erythromycin  
ABBOTICIN 
ERMYSIN 
1988 S. pneumoniae 
 
 NPD del Prado et al. 
2010 
 
gentamicin 
GENSUMYCIN 
GENTAMICIN B 
SEPTOMAL 
1963 S. aureus 
 
P. aeruginosa 
 Natural McConeghy and 
LaPlante 2010, 
LaPlante and 
Woodmansee 
2009 
Cai et al. 2009 
imipenem  
IMIPENEM 
TIENAM 
1985 P. aeruginosa 2-4 mg/l NPD Pereira et al. 2011 
levofloxacin 
LEVOFLOXACIN 
TAVANIC 
1993 S. aureus  
P. aeruginosa  
 
1-64 mg/l  
1-2 mg/l  
 
Synthetic Cafiso et al. 2010 
King et al. 2010 
 
linezolid  
ZYVOXID 
2000 S. aureus 
S. epidermidis 
0.5-64 mg/l 
18 mg/l 
Synthetic Cafiso et al. 2010 
Leite et al. 2011a 
meropenem 
MERONEM 
MEROPENEM 
1994 P. aeruginosa 16 mg/l NPD Moskowitz et al. 
2011 
moxifloxacin  
AVELOX 
VIGAMOX 
1999 S. aureus 0.06-4 mg/l Synthetic Morrow et al. 
2011 
mupirocin  
BACTROBAN 
1985 S. aureus,  
S. epidermidis 
0.06-0.12 
 
Natural Hurdle et al. 2009 
nitrofurantoin 
NITROFUR-C 
1978 E. coli  Synthetic Blango and 
Mulvey 2010 
norfloxacin  
NORFLOXACIN 
1983 S. epidermidis 
P. aeruginosa 
50 mg/l 
3.125 mg/l 
Synthetic Yassien and 
Khardori 2001 
Yassien et al. 1995 
ofloxacin  
TARIVID 
1985 S. epidermidis 
P. aeruginosa 
6.25 mg/l 
12.5 mg/l 
Synthetic Yassien and 
Khardori 2001 
Yassien et al. 1995 
rifampicin 
RIMAPEN 
1959 S. aureus 
S. epidermidis 
1-16 mg/l 
10 mg/l 
NPD Cafiso et al. 2010 
Leite et al. 2011a 
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tazobactam –
piperacillin 
PIPERACILLIN/ 
TAZOBACTAM 
TAZOCIN 
1992 P. aeruginosa  
 
 NPD Jang et al. 2009 
teicoplanin  
TARGOCID 
1988 S. aureus,  
S. epidermidis 
0.5 mg/l Natural Lee et al. 2006 
tetracycline 
APOCYCLIN 
ORICYCLIN 
1945 S. epidermidis  
P. aeruginosa 
 Natural Monzón et al. 
2002 
Liaqat et al. 2009 
tigecycline  
TYGACIL 
 
2005 S. aureus 
E. faecalis 
Candida albicans 
0.06-1 mg/l 
4 mg/l  
512 mg/l  
NPD Cafiso et al. 2010 
Minardi et al. 
2011 
Ku et al. 2010 
trimethoprim-
sulfamethoxazole 
COTRIM 
1960 S. aureus 
S. epidermidis 
 Synthetic del Pozo et al. 
2009 
tobramycin 
TOBI 
TOBRAMYCIN B 
TOMYCIN 
1975 S. aureus 
P. aeruginosa  
 
2-128 mg/l 
 
Natural Cafiso et al. 2010 
Herrmann et al. 
2010 
 
vancomycin 
VANCOMYCIN 
VANCOSAN 
1956 S. aureus, 
S. epidermidis  
 
2 mg/l 
2 mg/l 
Natural Aybar et al. 2012, 
Rose and Poppens 
2009, Tang et al. 
2011, Giacometti 
et al. 2005 
a
year developed or launched (can be an old drug launched for a new purpose). 
b
NPD – natural product derivative 
c
References for the reported anti-biofilm activity of the compounds.
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